Supporting Information

Generation and Precise Control of Sulfonyl Radicals: Visible-Light-Activated Redox-Neutral Formation of Sulfonates and Sulfonamides

Mingjun Zhang,^a Xin Ding,^a Aidang Lu,^b Jin Kang,^a Yongyue Gao,^a Ziwen Wang,^{*a} Hongyan Li^{*b} and Qingmin Wang^{*c}

^aTianjin Key Laboratory of Structure and Performance for Functional Molecules, College of

Chemistry, Tianjin Normal University, Tianjin 300387, China;

^bNational-Local Joint Engineering Laboratory for Energy Conservation in Chemical Process

Integration and Resources Utilization, School of Chemical Engineering and Technology, Hebei

University of Technology, Tianjin 300130, China;

^cState Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, College of Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin 300071, China.

* To whom correspondence should be addressed. For Ziwen Wang, E-mail: hxxywzw@tjnu.edu.cn; Phone: 0086-22-23766531; Fax: 0086-22-23766531; For Hongyan Li, E-mail: hyli@hebut.edu.cn; Phone: 0086-22-60302812; Fax: 0086-22-60204274; For Prof. Qingmin Wang, E-mail: wangqm@nankai.edu.cn; Phone: 0086-22-23503952; Fax: 0086-22-23503952.

Contents

1. General Information	4
2. Preparation of Photocatalyst and Substrate	4
2.1 Preparation of photocatalysts Ir(btp) ₂ Ala, Ir(btp) ₂ Gly, Ir(btp) ₂ Leu a	ınd
Ir(btp) ₂ (<i>t</i> -Leu)	4
2.1.1 General Procedure 1 for Preparation of 2-(benzo[b]thiophen-2-yl)pyri	id-
ine (L1)	4
2.1.2 General Procedure 2 for Preparation of Ir(btp) ₂ Cl (L2)	5
2.1.3 General Procedure 3 for Preparation of Ir(btp) ₂ Ala, Ir(btp) ₂ G	ily,
Ir(btp) ₂ Leu and Ir(btp) ₂ (t-Leu) and Determination of Excited State Potenti	als
of Ir(btp) ₂ Ala	6
2.2 Preparation of Substrates	10
2.2.1 General Procedure 4 for Preparation of Substrates 1a-1o, 1r, 1s, 1x a	ınd
1z	10
2.2.2 General Procedure 5 for Preparation of Substrates 1p and 1q	16
2.2.3 General Procedure 6 for Preparation of S4a	18
2.2.4 General Procedure 7 for Preparation of Substrates 1t-1q	19
2.2.5 General Procedure 8 for Preparation of Substrates 1y	21
2.2.6 General Procedure 9 for Preparation of Substrates 1cc	22
3. Investigation of the Key Reaction Parameters	23
4. Investigation of the mechamism	25
4.1 General Procedure 10 for Mechanistic Study (a)	25
4.2 General Procedure 11 for Mechanistic Study (b)	26
4.3 General Procedure 12 for Mechanistic Study (c)	26
4.4 General Procedure 13 for Mechanistic Study (d)	27
4.5 General Procedure 14 for Mechanistic Study (e)	27
4.6 General Procedure 15 for Mechanistic Study (f)	28
4.7 General Procedure 16 for Mechanistic Study (g)	29
4.8 General Procedure 17 for Mechanistic Study (h)	29

4.9 Scheme S1: Proposed Mechanism of 3t	30
4.10 Light on/off experiment (3a)	
4.11 Light on/off experiment (4a)	
4.12 Stern-Volmer Measurements	
5. Experimental Procedures and Product Characterization	
5.1 General Procedure 18 for Sulfonation of Substrates 1	
5.2 General Procedure 19 for Sulfonamidation of Substrates 1	
5.3 General Procedure 20 for Sulfonylation of Substrates 5a-5g	
5.4 General Procedure 21 for Sulfonylation of Substrates 5k	59
6. MS (ESI) spectrum	61
7. ¹ H NMR and ¹³ C NMR spectrum of Photocatalysts	62
8. ¹ H NMR and ¹³ C NMR spectrum of Substrates	67
9. ¹ H NMR and ¹³ C NMR spectrum of Mechanistic Study	95
10. ¹ H NMR and ¹³ C NMR spectrum of Sulfonate Products	99
11. ¹ H NMR and ¹³ C NMR spectrum of Alkylsulfonamide Products	
12. ¹ H NMR and ¹³ C NMR spectrum of Sulfonyl Products	1499

1. General Information

All commercially available reagents were used without further purification unless mentioned otherwise. ¹H and ¹³C Nuclear Magnetic Resonance (NMR) spectra were recorded on Bruker Avance 400 Ultrashield NMR spectrometer. Chemical shifts (δ) were given in parts per million (ppm) and were measured downfield from internal tetramethylsilane. The melting points were determined on an X-4 microscope melting point apparatus and are uncorrected. Conversion was monitored by thin layer chromatography (TLC). Flash column chromatography was performed over silica gel (100-200 mesh). Blue LED (25 W, λ max = 480 nm), purchased from JIADENG (LS), was used for blue light irradiation. A fan attached to the apparatus was used to maintain the reaction temperature at room temperature.

2. Preparation of Photocatalyst and Substrate.

2.1 Preparation of photocatalysts Ir(btp)₂Ala, Ir(btp)₂Gly, Ir(btp)₂Leu and Ir(btp)₂(*t*-Leu).

The photocatalysts were synthesized according to the following method. The other photocatalysts $Ir\{dF(CF_3)ppy\}_2(dtbbpy)PF_6$, $Ir(dtbbpy)(ppy)_2PF_6$, Eosin Y, $Ru(bpy)_3(PF_6)_2$, $Ir(ppy)_3$ and Mes-Acr⁺ are commercially available.

2.1.1 General Procedure 1 for Preparation of 2-(benzo[b]thiophen-2-yl)pyridine (L1).



To a 50 mL round-bottom flask was added 2-bromopyridine (1.0 g, 6.25 mmol, 1.0 equiv), benzo[b]thiophene-2-boronic acid (1.2 g, 6.88 mmol, 1.1 equiv), Na₂CO₃ (1.99 g, 18.75 mmol, 3.0 equiv), (beta-4)-platinum (0.72 g, 0.62 mmol, 10 % mol), toluene (10 mL), EtOH (5 mL) and H₂O (5 mL) under argon atmosphere. The mixture was refluxed (100 $^{\circ}$ C) with stirring for 12 h, then cooled to room temperature. The residue was taken into H₂O (20 mL), extracted with DCM (10 mL \times 3). The combined organic phase was dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (10:1,v/v) as the eluent to give 2-(benzo[*b*]thiophen-2-yl)pyridine (1.16 g, 5.5 mmol, 88 %).

2-(Benzo[b]thiophen-2-yl)pyridine (L1).



General procedure 1 was followed to obtain L1 (1.16 g, 5.5 mmol, 88 %) as a white solid.

¹**H** NMR (400 MHz, CDCl₃) δ 8.64 (d, J = 4.7 Hz, 1H, Ar-H), 7.90 – 7.86 (m, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 7.83 – 7.79 (m, 2H, Ar-H), 7.76 – 7.72 (m, 1H, Ar-H), 7.38 – 7.33 (m, 2H, Ar-H), 7.23 – 7.20 (m, 1H, Ar-H).

2.1.2 General Procedure 2 for Preparation of Ir(btp)₂Cl (L2).



To a 50 mL round-bottom flask was added 2-eyhoxyethanol (9 mL), H₂O (3 mL), IrCl₃.3H₂O (1.0 g, 3.2 mmol, 1.0 equiv), and 2-(benzo[*b*]thiophen-2-yl)pyridine (1.5 g, 7.0 mmol, 2.2 equiv) under argon atmosphere. The mixture was refluxed (140 $^{\circ}$ C) with stirring for 12 h, then cooled to room temperature. The mixture was filtered, washed with water (20 mL) and ethanol (20 mL), to get Ir(btp)₂Cl (1.88 g, 0.15 mmol, 90%).

Ir(btp)₂Cl (L2)



General procedure 2 was followed to obtain L2 (1.46 g, 0.11 mmol, 70%) as a red solid. Mp > 300 °C.

¹**H NMR** (400 MHz, DMSO-d6) δ 9.93 (d, J = 5.4 Hz, 2H, Ar-H), 9.69 (d, J = 5.3 Hz, 2H, Ar-H), 8.17 (td, J = 8.0, 1.5 Hz, 2H, Ar-H), 8.09 (td, J = 7.8, 1.4 Hz, 2H, Ar-H), 7.92 (d, J = 7.6 Hz, 2H, Ar-H), 7.83 – 7.77 (m, 6H, Ar-H), 7.52 (ddd, J = 7.4, 5.9, 1.4 Hz, 2H, Ar-H), 7.45 (ddd, J = 7.4, 6.0, 1.5 Hz, 2H, Ar-H), 7.21 – 7.16 (m, 2H, Ar-H), 7.12 (m, 2H, Ar-H), 6.93 – 6.88 (m, 2H, Ar-H), 6.81 – 6.74 (m, 2H, Ar-H), 6.19 (d, J = 8.0 Hz, 2H, Ar-H), 5.55 (d, J = 8.2 Hz, 2H, Ar-H).¹³**C NMR** (100 MHz, DMSO-*d6*) δ 164.7, 163.6, 153.0, 152.1, 146.7, 144.8, 144.3, 141.9, 141.8, 141.1, 140.7, 139.5, 136.5, 135.5, 125.7, 124.8, 124.6, 124.2, 123.9, 123.3, 123.1, 121.3, 121.0, 119.5, 119.4. **HRMS** (ESI) calcd for C₅₂H₃₃Cl₂Ir₂N₄S₄ [M+H]⁺ 1297.0218, found 1297.0224. 2.1.3 General Procedure 3 for Preparation of Ir(btp)₂Ala, Ir(btp)₂Gly, Ir(btp)₂Leu and Ir(btp)₂(*t*-Leu).



To a 50 mL round-bottom flask was added corresponding acids A1-A4 (0.85 mmol, 1.0 equiv), NaHCO₃ (0.07 g, 0.85 mmol, 1.0 equiv) and MeOH (10 mL). The mixture was stirred at room temperature for 3 h, concentrated to 3 ~5 mL under reduced pressure and got the corresponding concentrated methanol solution of L2-L5.



To a 50 mL round-bottom flask was added L2 (0.5 g, 0.39 mmol, 1.0 equiv), 2-eyhoxyethanol (10 mL), and the concentrated methanol solution of corresponding L2-L5 (0.85 mmol, 1.1 equiv) under argon atmosphere. The mixture was refluxed at 140 $^{\circ}$ C with stirring for 12~24 h and concentrated. The residue was purified by flash chromatography on a silica gel using DCM and methanol (50:1, v/v) as the eluent to give PC1-PC4.

Ir(btp)₂Ala (PC1)



General procedure 3 was followed to obtain PC1 (0.34 g, 0.49 mmol, 62%) as a red solid. Mp > 300 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 9.14 (d, J = 5.7 Hz, 1H, Ar-H), 8.66 (d, J = 5.7 Hz, 1H, Ar-H), 8.04 – 7.99 (m, 2H, Ar-H), 7.89 – 7.85 (m, 1H, Ar-H), 7.83 – 7.74 (m, 3H, Ar-H), 7.40 – 7.36 (m, 1H, Ar-H), 7.35 – 7.30 (m, 1H, Ar-H), 7.13 – 7.06 (m, 2H, Ar-H), 6.87 – 6.83 (m, 1H, Ar-H), 6.78 – 6.74 (m, 1H, Ar-H), 6.20 (d, J = 8.1 Hz, 1H, Ar-H), 5.82 (d, J = 8.2 Hz, 1H, Ar-H), 5.73 (dd, J = 11.9, 7.8 Hz, 1H, NH), 3.41 – 3.37 (m, 1H, CH), 1.18 (d, J = 7.0 Hz, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 182.6, 165.5, 165.3, 152.0, 148.3, 146.7, 146.5, 145.6, 141.7, 141.6, 139.0, 135.2, 125.3, 124.9, 123.5, 123.5, 122.8, 120.1, 119.8, 118.7, 118.7, 62.8, 21.2. **HRMS** (ESI) calcd for C₂₉H₂₂IrN₃O₂S₂ [M+H]⁺ 701.0777, found 701.0782.

Cyclic Voltammetry and Determination of Excited State Potentials:

Cyclic voltammograms were acquired on a CH Instruments 700E potentiostat using a glassy carbon working electrode, a saturated calomel (SCE) reference electrode, and a Pt mesh counter electrode. The pH was not adjusted and voltammograms were obtained at room temperature in a 100 mM MeCN solution of tetrabutylammonium hexafluorophosphate containing 1 mM of the designated substances. The scan rate was 50 mV/s.



Cyclic voltammogram of ferrocence in acetonitrile solution (1.0×10^{-3} M) at room temperature. $E_{ox(Fc/Fc^+)} = 0.372$ V vs SCE in acetonitrile, the reported value is $E_{ox(Fc/Fc^+)}$

= 0.38 V vs SCE in acetonitrile.¹



Cyclic voltammogram of Ir(btp)₂ala in acetonitrile solution (1.0×10^{-3} M) at room temperature. Ir(III)/Ir(IV) $E_{pc} = 0.573$ V, $E_{pa} = 0.802$ V, Ir(II)/Ir(III) $E_{pa} = -0.735$ V, $E_{pc} = -0.878$ V. $E_{1/2}^{ax}$ III/II and $E_{1/2}^{red}$ IV/III values: -0.85 and +0.774 V (vs. SCE).



Normalized emission spectra of $Ir(btp)_2ala$ in acetonitrile solution (1.0×10^{-5} M) at room temperature. The maxima was obtained at 595 nm; the intensity is 10% of the emission maxima at 530 nm.

Excited state potentials are estimated using the Rehm-Weller equations as given²:

$$E_{\text{ox}}^* = E_{\text{ox}}^* - E_{\text{ox}}^{0-0}$$

 $E_{\text{red}}^* = E_{\text{red}}^* - E_{\text{ox}}^{0-0}$

The E* means the excited state potential, E' means the ground state potential, E^{0-0} represents the energy gap between the zeroeth level vibrational levels of the ground and excited state. E_{ox} is to mean the Ir(III)/Ir(IV) couples and E_{red} is to mean the

Ir(II)/(III) couples. Because of poor overlap between the absorbtion and emission spectra, E^{0-0} is approximated as the high-energy onset of phosphorescence where the emission intensity is 10% of that obtained at the maximum emission wavelength, using the "10% rule"^{3,1b}. Base on the above methods: $E_{1/2}^{*III/II}$, $E_{1/2}^{III/II}$, $E_{1/2}^{III/III}$, $E_{1/2}^{III/II}$

Ir(btp)₂Gly (PC2)



General procedure 3 was followed to obtain PC2 (0.27 g, 0.40 mmol, 52%) as a red solid. Mp > 300 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 9.10 (d, J = 5.6 Hz, 1H, Ar-H), 8.70 (d, J = 5.6 Hz, 1H, Ar-H), 8.06 – 8.00 (m, 2H, Ar-H), 7.87 (d, J = 8.0 Hz, 1H, Ar-H), 7.81 – 7.76 (m, 3H, Ar-H), 7.41 – 7.38 (m, 1H, Ar-H), 7.35 – 7.32 (m, 1H, Ar-H), 7.13 – 7.07 (m, 2H, Ar-H), 6.87 – 6.83 (m, 1H, Ar-H), 6.79 – 6.74 (m, 1H, Ar-H), 6.20 (d, J = 8.1 Hz, 1H, Ar-H), 5.84 (d, J = 8.1 Hz, 1H, Ar-H), 5.49 – 5.16 (m, 1H, NH), 3.28 (dd, J = 13.2, 6.7 Hz, 2H, CH₂). ¹³**C NMR** (100 MHz, CDCl₃) δ 182.4, 165.9, 165.5, 152.1, 151.7, 149.3, 147.98, 146.96, 145.9, 142.2, 142.1, 139.6, 135.8, 133.9, 125.7, 125.4, 124.1, 124.05, 123.4, 120.8, 120.4, 119.2, 63.3. **HRMS** (ESI) calcd for C₂₈H₂₀IrN₃O₂S₂ [M+H]⁺ 687.0621, found 687.0623.

Ir(btp)₂Leu (PC3)



General procedure 3 was followed to obtain PC3 (0.27 g, 0.37 mmol, 47 %) as a red solid. Mp > 300 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 9.16 (d, J = 4.4 Hz, 1H, Ar-H), 8.63 (d, J = 5.2 Hz, 1H, Ar-H), 8.02 (d, J = 7.0 Hz, 2H, Ar-H), 7.87 (t, J = 7.8 Hz, 1H, Ar-H), 7.80 – 7.76 (m, 3H, Ar-H), 7.36 (d, J = 5.2 Hz, 2H, Ar-H), 7.13 – 7.08 (m, 2H, Ar-H), 6.86 (t, J = 7.6 Hz, 1H, Ar-H), 6.76 (t, J = 7.8 Hz, 1H, Ar-H), 6.24 (d, J = 8.2 Hz, 1H, Ar-H), 5.93 – 5.81 (m, 1H, NH), 5.80 (d, J = 7.6 Hz, 1H, Ar-H), 3.51 – 3.47 (m, 1H, NH-CH), 1.26 – 1.24 (m, 2H, CH₂), 0.91 – 0.81 (m, 6H, CH₃), 0.77 – 0.76 (m, 1H, CH). ¹³C NMR (100 MHz, DMSO-*d6*) δ 182.7, 165.5, 151.9, 151.8, 148.3, 146.9, 146.5, 141.7, 141.6, 139.0, 135.2, 133.5, 125.5, 124.8, 123.5, 122.8, 122.78, 119.7, 118.7, 69.8, 52.8, 40.2, 40.0, 39.7, 39.5, 39.3, 39.1, 38.9, 23.5, 20.8. HRMS (ESI) calcd for C₃₂H₂₈IrN₃O₂S₂ [M+H]⁺ 743.1247, found 743.1252.

Ir(btp)₂(*t*-Leu) (PC4)



General procedure 3 was followed to obtain PC4 (0.33 g, 0.45 mmol, 58%) as a red solid. Mp > 300 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 9.22 (d, J = 5.7 Hz, 1H, Ar-H), 8.65 (d, J = 5.7 Hz, 1H, Ar-H), 8.04 – 7.99 (m, 2H, Ar-H), 7.87 (d, J = 8.0 Hz, 1H, Ar-H), 7.79 – 7.75 (m, 3H, Ar-H), 7.36 – 7.31 (m, 2H, Ar-H), 7.12 – 7.07 (m, 2H, Ar-H), 6.87 – 6.83 (m, 1H, Ar-H), 6.78 – 6.74 (m, 1H, Ar-H), 6.22 (d, J = 8.1 Hz, 1H, Ar-H), 5.79 (d, J = 8.1 Hz, 1H, Ar-H), 5.75 (dd, J = 12.2, 8.0 Hz, 1H, NH), 2.99 (t, J = 8.9 Hz, 1H, CH), 0.96 (s, 9H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 180.8, 166.3, 165.9, 152.8, 151.8, 149.0, 147.4, 146.9, 142.2, 142.1, 139.4, 135.6, 134.1, 126.0, 125.5, 125.3, 125.2, 124.0, 123.9, 123.3, 123.26, 120.6, 119.8, 119.3, 119.1, 63.3, 35.5, 27.5. **HRMS** (ESI) calcd for C₃₂H₂₈IrN₃O₂S₂ [M+H]⁺ 743.1247, found 743.1242.

2.2 Preparation of Substrates.

2.2.1 General Procedure 4 for Preparation of Substrates **1a–1o**, **1r**, **1s**, **1x** and **1z**. Method A:



To a 50 mL round-bottom flask was added the solution of corresponding aniline S1 (2.0 mmol) in DCM (15 mL) and triethylamine (0.4 g, 4.0 mmol, 2.0 equiv). The mixture was stirred at 0 °C, and added methacryloyl chloride S2a (0.31 g, 3.0 mmol, 1.5 equiv) slowly under argon atmosphere. The resulting solution was stirred at room temperature for 6~12 h, quenched with H₂O (50 mL), extracted with DCM (15 mL × 3). The combined organic layer was washed with brine (15 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (15:1~10:1, v/v) as the eluent to give corresponding substrates **1a–10**.

Method B:



To a 50 mL round-bottom flask was added the solution of corresponding *N*-methyl-4-nitroaniline S1a (2.0 mmol) in benzene (15 mL) and K₂CO₃ (0.42 g, 3.0 mmol, 1.5 equiv). The mixture was stirred and added slowly with acryloyl chloride S2a (0.31 g, 3.0 mmol, 1.5 equiv) under argon atmosphere. Then the reaction mixture was refluxed at 80 °C for 12~24 h, cooled to room temperature, and quenched with water (50 mL). The result solution was extracted with DCM (15 mL × 3). The combined organic layer was washed with brine (15 mL × 3), dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (15:1~10:1, v/v) as the eluent to give corresponding substrates **1h–1k**.

N-Methyl-N-phenylmethacrylamide (1a)



General procedure 4 (A) was followed to obtain 1a (0.31 g, 1.77 mmol, 95 %) as a white solid. Mp 60–61 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.37 – 7.33 (m, 2H, Ar-H), 7.28 – 7.25 (m, 1H, Ar-H), 7.15 (d, J = 1.4 Hz, 1H, Ar-H), 7.13 (d, J = 1.1 Hz, 1H, Ar-H), 5.04 (s, 1H, =CH₂), 4.99 (s, 1H, =CH₂), 3.35 (s, 3H, N-CH₃), 1.76 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 172.0, 144.7, 140.7, 129.2, 126.9, 126.5, 119.4, 37.7, 20.3.

N-(4-Fluorophenyl)-*N*-methylmethacrylamide (1b)



General procedure 4 (A) was followed to obtain 1b (0.27 g, 1.41 mmol, 88%) as a dark brown oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.13 (d, J = 4.9 Hz, 1H, Ar-H), 7.10 (d, J = 4.9 Hz, 1H, Ar-H), 7.06 (d, J = 4.9 Hz, 1H, Ar-H), 7.02 (d, J = 4.9 Hz, 1H, Ar-H), 5.06 (s, 1H, =CH₂), 4.98 (s, 1H, =CH₂), 3.32 (s, 3H, N-CH₃), 1.77 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.9, 162.4, 159.9, 140.5, 128.3, 128.2, 119.4, 116.2, 116.0, 37.8, 20.3.

N-(4-Chlorophenyl)-N-methylmethacrylamide (1c)



General procedure 4 (A) was followed to obtain **1c** (0.27 g, 1.29 mmol, 91%) as a white solid. **Mp** 60–61 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.47 (d, J = 8.7 Hz, 2H, Ar-H), 7.02 (d, J = 8.7 Hz, 2H, Ar-H), 5.11 – 5.04 (m, 1H, =CH₂), 5.01 – 4.96 (m, 1H, =CH₂), 3.33 (s, 3H, N-CH₃), 1.81 – 1.77 (m, 3H, CH₃). ¹³**C** NMR (100 MHz, CDCl₃) δ 171.8, 143.2, 140.4, 132.5, 129.4, 127.7, 119.7, 37.6, 20.3.

N-(4-Bromophenyl)-N-methylmethacrylamide (1d)



General procedure 4 (A) was followed to obtain **1c** (0.28 g, 1.10 mmol, 97%) as a purple solid. **Mp** 77–78 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.47 (d, J = 8.7 Hz, 2H, Ar-H), 7.02 (d, J = 8.7 Hz, 2H, Ar-H), 5.11 – 5.04 (m, 1H, =CH₂), 5.01 – 4.96 (m, 1H, =CH₂), 3.33 (s, 3H, N-CH₃),

1.81 – 1.77 (m, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 171.8, 143.7, 140.4, 132.4, 128.1, 120.4, 119.8, 37.6, 20.3.

N-(4-Iodophenyl)-N-methylmethacrylamide (1e)



General procedure 4 (A) was followed to obtain **1e** (0.24 g, 0.80 mmol, 91%) as a brown solid. **Mp** 107–108 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.66 (d, J = 8.4 Hz, 2H, Ar-H), 6.89 (d, J = 8.5 Hz, 2H, Ar-H), 5.08 (s, 1H, =CH₂), 4.99 (s, 1H, =CH₂), 3.32 (s, 3H, N-CH₃), 1.78 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.8, 144.4, 140.3, 138.4, 128.3, 119.9, 91.6, 77.4, 77.1, 76.7, 37.6, 21.5, 20.3.

N-Methyl-N-(p-tolyl)methacrylamide (1f)



General procedure 4 (A) was followed to obtain 1f (0.30 g, 1.59 mmol, 96%) as a yellow oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.14 (d, J = 8.1 Hz, 2H, Ar-H), 7.02 (d, J = 8.3 Hz, 2H, Ar-H), 5.02 (s, 1H, =CH₂), 4.99 (s, 1H, =CH₂), 3.32 (s, 3H, N-CH₃), 2.35 (s, 3H, Ar-CH₃), 1.76 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 172.0, 142.1, 140.8, 136.8, 129.8, 126.3, 119.1, 37.7, 21.0, 20.4.

N-(4-Methoxyphenyl)-*N*-methylmethacrylamide (1g)



General procedure 4 (A) was followed to obtain 1g (0.32 g, 1,53 mmol, 92%) as a purple oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.05 (d, J = 8.9 Hz, 2H, Ar-H), 6.86 (d, J = 8.9 Hz, 2H, Ar-H), 5.03 (s, 1H, =CH₂), 4.99 (s, 1H, =CH₂), 3.81 (s, 3H, O-CH₃), 3.31 (s, 3H, N-CH₃), 1.74 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 172.3, 158.3, 140.8, 127.7, 114.4, 77.5, 77.1, 76.8, 55.4, 20.4.

N-(4-Cyanophenyl)-N-methylmethacrylamide (1h)



General procedure 4 (B) was followed to obtain **1h** (0.24 g, 1.20 mmol, 79%) as a white solid. **Mp** 80–81 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.65 (d, J = 8.7 Hz, 2H, Ar-H), 7.26 (d, J = 6.3 Hz, 2H, Ar-H), 5.15 (m, 1H, =CH₂), 5.00 – 4.99 (m, 1H, =CH₂), 3.39 (s, 3H, N-CH₃), 1.88 – 1.79 (m, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.7, 148.7, 140.1, 133.2, 126.5, 120.5, 118.2, 110.1, 37.4, 20.1.

N-Methyl-N-(4-(trifluoromethyl)phenyl)methacrylamide (1i)



General procedure 4 (B) was followed to obtain 1i (0.26 g, 1.06 mmol, 93%) as a yellow oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.61 (d, J = 8.4 Hz, 2H, Ar-H), 7.27 (d, J = 3.4 Hz, 2H, Ar-H), 5.15 – 5.07 (m, 1H, =CH₂), 5.04 – 4.95 (m, 1H, =CH₂), 3.38 (s, 3H, N-CH₃), 1.87 – 1.77 (m, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.8, 147.8, 140.2, 128.6 (q, J = 432.9 Hz), 126.4, 126.3 (q, J = 3.7 Hz), 120.2, 37.5, 20.2.

N-Methyl 4-(N-methylmethacrylamido)benzoate (1j)



General procedure 4 (B) was followed to obtain **1j** (0.23 mg, 1.0 mmol, 83%) as a white solid. **Mp** 58–59 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.02 (d, J = 8.6 Hz, 2H, Ar-H), 7.21 (d, J = 8.6 Hz, 2H, Ar-H), 5.10 – 5.07 (m, 1H, =CH₂), 5.02 – 4.97 (m, 1H, =CH₂), 3.92 (s, 3H, -OCH₃), 3.39 (s, 3H, N-CH₃), 1.84 – 1.78 (m, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.8, 166.2, 148.8, 140.4, 130.7, 128.3, 125.9, 120.1, 52.2, 37.4, 20.1.

N-Methyl-N-(4-nitrophenyl)methacrylamide (1k)



General procedure 4 (B) was followed to obtain 1k (0.22 g, 0.10 mmol, 83%) as a yellow solid. Mp 76–77 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 8.23 (d, J = 9.1 Hz, 2H, Ar-H), 7.31 (d, J = 9.1 Hz, 2H, Ar-H), 5.19– 5.15 (m, 1H, =CH₂), 5.04 – 4.99 (m, 1H, =CH₂), 3.42 (s, 3H, N-CH₃), 1.90 – 1.85 (m, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 171.72, 150.40, 145.50, 140.02, 126.14, 124.69, 120.70, 37.44, 20.07.

N-(2-Fluorophenyl)-N-methylmethacrylamide (11)



General procedure 4 (A) was followed to obtain 11 (0.30 g, 1.55 mmol, 97 %) as a yellow oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.30 – 7.26 (m, 1H, Ar-H), 7.20 – 7.08 (m, 3H, Ar-H), 5.01 (s, 1H, =CH₂), 4.94 (s, 1H, =CH₂), 3.30 (s, 3H, N-CH₃), 1.83 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.9, 143.5, 141.2, 129.1, 127.2, 126.5, 120.9, 29.7, 19.9.

N-(2,4-Difluorophenyl)-*N*-methylmethacrylamide (1m)



General procedure 4 (A) was followed to obtain 1m (0.26 g, 1.23 mmol, 88 %) as a yellow oil.

¹**H** NMR (400 MHz, CDCl₃) δ 6.75 (d, J = 1.8 Hz, 1H, Ar-H), 6.72 (d, J = 1.8 Hz, 1H, Ar-H), 6.70 (s, 1H, Ar-H), 5.15 (s, 1H, =CH₂), 5.05 (s, 1H, =CH₂), 3.34 (s, 3H, N-CH₃), 1.84 (s, 3H, CH₃). ¹³**C** NMR (100 MHz, CDCl₃) δ 171.7, 164.3, 164.2, 161.8, 161.7, 146.9, 140.2, 127.1, 120.0, 37.5, 20.1.

N-([1,1'-Biphenyl]-2-yl)-*N*-methylmethacrylamide (1n)



General procedure 4 (A) was followed to obtain 1n (0.25 g, 1.0 mmol, 92 %) as a white solid. Mp 105–106 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.28 (m, 8H, Ar-H), 4.93 (s, 1H, =CH₂), 4.67 (s, 1H, =CH₂), 3.27 (s, 3H, N-CH₃), 1.30 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ

170.9, 142.3, 140.0, 138.8, 131.3, 128.9, 128.7, 128.4, 128.1, 127.6, 127.5, 119.6, 38.4, 19.7.

N-Methyl-N-(naphthalen-1-yl)methacrylamide (10)



General procedure 4 (A) was followed to obtain **10** (0.28 g, 1.24 mmol, 98 %) as a brown solid. **Mp** 103–104 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.84 – 7.79 (m, 2H, Ar-H), 7.38 – 7.34 (m, 1H, Ar-H), 7.53 – 7.45 (m, 2H, Ar-H), 7.36 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.19 (d, , *J* = 8.0 Hz, 1H, Ar-H), 4.83 (s, 1H, =CH₂), 4.69 (s, 1H, =CH₂), 3.34 (s, 3H, N-CH₃), 1.62 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.0, 141.0, 140.5, 134.6, 130.2, 128.7, 128.3, 127.2, 126.5, 125.6, 125.4, 122.8, 117.9, 37.6, 20.4.

2.2.2 General Procedure 5 for Preparation of Substrates 1p and 1q.



To a 50 mL round-bottom flask was added the solution of corresponding aniline S3 (2.0 mmol) in DCM (15 mL) and triethylamine (0.4 g, 4.0 mmol, 2.0 equiv). The mixture was stirred at 0 °C, and added slowly methacryloyl chloride S2a (0.25 g, 2.4 mmol, 1.2 equiv) under argon atmosphere. The resulting solution was stirred at room temperature for 6 h, quenched with H₂O (50 mL), and extracted with DCM (15 mL × 3). The combined organic layer was washed with brine (15 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (5:1, v/v) as the eluent to give corresponding intermediates, which were directly used for the next step.

To a 50 mL round-bottom flask was added the solution of corresponding intermediates (2.0 mmol) in THF (10 mL). The mixture was stirred at 0 °C, and added slowly NaH (0.07 g, 3.0 mmol, 1.5 equiv). Then the reaction mixture was stirred at 0 °C for 30 min, and added MeI (0.43 g, 3.0 mmol, 1.5 equiv). The resulting solution was stirred at room temperature for 8 h, quenched with H₂O (50 mL), and extracted with DCM (15 mL \times 3). The combined organic layer was washed with brine (15 mL \times 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash

chromatography on a silica gel using petroleum ether and ethyl acetate (10:1, v/v) as the eluent to give corresponding compounds **1p** and **1q**.

N-Methyl-N-(pyridin-2-yl)methacrylamide (1p)



General procedure 5 was followed to obtain **1p** (0.14 g, 0.79 mmol, 42 %) as a brown solid. **Mp** 77–78 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.46 (d, J = 4.8 Hz, 1H, Ar-H), 7.68 – 7.64 (m, 1H, Ar-H), 7.15 (d, J = 7.7 Hz, 1H, Ar-H), 7.14 – 7.10 (m, 1H, Ar-H), 5.08 (s, 1H, =CH₂), 5.00 (s, 1H, =CH₂), 3.45 (s, 3H, N-CH₃), 1.90 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 172.3, 156.7, 148.7, 141.1, 137.6, 121.2, 120.3, 119.1, 35.4, 20.0.

N-Methyl-N-(quinolin-2-yl)methacrylamide (1q)



General procedure 5 was followed to obtain 1q (0.18 g, 0.80 mmol, 46 %) as a brown solid. Mp 140–141 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.08 (d, J = 8.7 Hz, 1H, Ar-H), 7.96 (d, J = 8.5 Hz, 1H, Ar-H), 7.79 (d, J = 8.1 Hz, 1H, Ar-H), 7.73 – 7.69 (m, 1H, Ar-H), 7.54 – 7.50 (m, 1H, Ar-H), 7.27 (d, J = 8.3 Hz, 1H, Ar-H), 5.09 (s, 1H, =CH₂), 5.04 (s, 1H, =CH₂), 3.58 (s, 3H, N-CH₃), 2.00 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 172.8, 155.7, 146.9, 141.4, 137.5, 130.0, 128.6, 127.4, 126.3, 126.2, 119.4, 119.0, 35.4, 20.0. **HRMS** (ESI) calcd for C₁₄H₁₅N₂O [M+H]⁺ 227.1179, found 227.1186.

1-(3,4-Dihydroquinolin-1(2H)-yl)-2-methylprop-2-en-1-one (1r)



General procedure 4 (A) was followed to obtain 1r (0.28 g, 1.38 mmol, 92 %) as a yellow solid. Mp 57–58 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.20 (d, J = 7.5 Hz, 1H, Ar-H), 7.13 (d, J = 7.1 Hz, 1H, Ar-H), 7.12 – 7.04 (m, 2H, Ar-H), 5.20 – 5.17 (m, 1H, =CH₂), 5.16 – 5.12 (m, 1H, =CH₂), 3.85 – 3.77 (t, J = 6.0 Hz, 2H), 2.77 (t, J = 6.7 Hz, 2H), 2.02 – 1.96 (m, 2H),

1.87 (s, 3H). ¹³**C NMR** (100 MHz, CDCl₃) *δ* 171.5, 141.4, 139.0, 131.4, 128.4, 125.9, 124.8, 124.2, 119.0, 44.0, 26.8, 24.0, 19.9.

1-(10,11-Dihydro-5*H*-dibenzo[*b*,*f*]azepin-5-yl)-2-methylprop-2-en-1-one (1s)



General procedure 4 (A) was followed to obtain 1s (0.25 g, 0.95 mmol, 93 %) as a colorless oil.

¹**H** NMR (400 MHz, CDCl₃) δ 7.31 – 7.14 (m, 8H, Ar-H), 5.14 (s, 1H, =CH₂), 5.09 (s, 1H, =CH₂), 3.45 (t, *J* = 8.0 Hz, 2H, CH₂), 2.88 (t, *J* = 8.0 Hz, 2H, CH₂), 1.84 (s, 3H, CH₃). ¹³**C** NMR (100 MHz, CDCl₃) δ 171.0, 140.7, 135.7, 130.1, 128.1, 127.8, 126.8, 118.9, 77.4, 77.1, 76.8, 30.8, 20.4.

2.2.3 General Procedure 6 for Preparation of S4a.



To a 50 mL round-bottom flask was added the solution of aniline S3a (5.0 g, 0.054 mol, 1.0 equiv) in DCM (30 mL) and triethylamine (10.87 g, 0.11 mol, 2.0 equiv). The mixture was stirred at 0°C, and added slowly chloride S2a (11.63 g, 0.081 mol, 1.5 equiv) under argon atmosphere. The resulting solution was stirred at room temperature for 12 h, followed by the addition of H₂O (50 mL) to quench excess acyl chloride, extracted with DCM (20 mL × 3). The combined organic layer was washed with brine (15 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (10:1, v/v) as the eluent to give S4a.

N-Phenylmethacrylamide (S4a)



General procedure 6 was followed to obtain **S4a** (8.2 g, 0.051 mol, 95 %) as a white solid. **Mp** 83–84 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.57 (dr, 1H, NH), 7.56 (d, J = 8.0 Hz, 2H, Ar-H), 7.33 (t, J = 7.9 Hz, 2H, Ar-H), 7.12 (t, J = 7.4 Hz, 1H, Ar-H), 5.79 (s, 1H, =CH₂), 5.50 – 5.42 (m, 1H, =CH₂), 2.06 (s, 3H, CH₃).

2.2.4 General Procedure 7 for Preparation of Substrates 1t-1q.



To a 50 mL round-bottom flask was added the solution of S4a (2.0 mmol) in THF (10 mL). The mixture was stirred at 0 $^{\circ}$ C, and added slowly NaH (3.0 mmol). Then S5 (2.4 mmol, 1.2 equiv) was added to the mixture. The resulting solution was stirred at room temperature for 2–8 h, followed by the addition of H₂O (50 mL) to quench excess NaH, and extracted with DCM (15 mL × 3). The combined organic layer was washed with brine (15 mL × 3), dried over Na₂SO₄, and concentrated. The solvent was removed under reduced pressure to get products **1t–1q**.

N,*N*-Diphenylmethacrylamide (1t)



General procedure 7 was followed to obtain **1t** (0.28 g, 1.17 mmol, 94 %) as a white solid. **Mp** 105–106 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.35 – 7.23 (m, 4H, Ar-H), 7.24 – 7.21 (m, 2H, Ar-H), 7.17 (d, J = 7.3 Hz, 4H, Ar-H), 5.23 (s, 1H, =CH₂), 5.17 (s, 1H, =CH₂), 1.84 (s, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 143.5, 141.2, 129.1, 127.2, 126.5, 121.0, 77.4, 77.0, 76.7, 20.0.

N-Benzyl-N-phenylmethacrylamide (1u)



General procedure 7 was followed to obtain 1u (0.29 g, 1.14 mmol, 92 %) as a yellow oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.29 – 7.27 (m, 1H, Ar-H), 7.26 – 7.25 (m, 3H, Ar-H), 7.24 – 7.20 (m, 4H, Ar-H), 7.00 – 6.95 (m, 2H, Ar-H), 5.05 – 5.02 (m, 1H, =CH₂),

5.02 - 5.01 (m, 1H, =CH₂), 4.97 (s, 2H, CH₂), 1.81 - 1.74 (m, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 143.2, 140.8, 137.6, 129.0, 128.8, 128.4, 127.5, 127.3, 127.1, 119.4, 53.2, 20.4.

Ethyl N-methacryloyl-N-phenylglycinate (1v)



General procedure 7 was followed to obtain 1a (0.29 g, 1.18 mmol, 95 %) as a yellow oil.

¹**H** NMR (400 MHz, CDCl₃) δ 7.35 (d, J = 10.1, 2H, Ar-H), 7.30 – 7.27 (m, 1H, Ar-H), 7.26 – 7.23 (m, 2H, Ar-H), 5.08 (d, J = 4.0, 2H, =CH₂), 4.44 (s, 2H, CH₂), 4.20 (q, J = 7.1 Hz, 2H, O-CH₂), 1.78 (s, 3H, CH₃), 1.28 (t, J = 7.1 Hz, 3H, OCH₂-CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 169.0, 143.6, 140.0, 129.2, 127.3, 127.1, 120.2, 61.3, 51.7, 20.1, 14.1.

N-Phenyl-*N*-tosylmethacrylamide (1w)



General procedure 7 was followed to obtain **1w** (0.36 g, 1.14 mmol, 92 %) as a white solid. **Mp** 128–129 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.78 (d, J = 8.4 Hz, 2H, Ar-H), 7.42 – 7.34 (m, 3H, Ar-H), 7.30 (d, J = 8.0 Hz, 2H, Ar-H), 7.16 – 7.14 (m, 1H, Ar-H), 7.14 – 7.12 (m, 1H, Ar-H), 5.37 – 5.36 (m, 1H, =CH₂), 5.30 – 5.20 (m, 1H, =CH₂), 2.44 (s, 3H, N-CH₃), 1.68 – 1.65 (m, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.9, 144.8, 139.4, 137.2, 135.3, 130.0, 129.4, 129.2, 129.19, 124.3, 21.7, 19.2.

N-(Benzo[*d*][1,3]dioxol-5-yl)-*N*-methylmethacrylamide (1x)



General procedure 4 (A) was followed to obtain 1x (0.27 g, 1.23 mmol, 92 %) as a brown solid. Mp 94–95 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 6.75 (d, J = 8.1 Hz, 1H, Ar-H), 6.63 (d, J = 2.0 Hz, 1H, Ar-H), 6.59 (dd, J = 8.1, 2.1 Hz, 1H, Ar-H), 6.00 (s, 2H, CH₂), 5.05 (s, 1H, =CH₂),

5.02 (s, 1H, =CH₂), 3.29 (s, 3H, N-CH₃), 1.78 (s, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 172.1, 148.1, 146.5, 140.8, 138.6, 120.1, 118.9, 108.2, 107.8, 101.7, 37.9, 20.4.

2.2.5 General Procedure 8 for Preparation of Substrates 1y.



S6a (2.0 mmol) and DCM (10 mL) were added to a 50 mL round-bottom flask. The mixture was stirred at 0 $^{\circ}$ C, and added slowly thionylchloride (3.0 mmol), then refluxed at 55 $^{\circ}$ C for 6 h. The solvent was removed under reduced pressure to get product S2b, which was used directly to the next step.

To a 50 mL round-bottom flask was added the solution of aniline **S1a** (2.0 mmol) in DCM (15 mL) and triethylamine (0.4 g, 4.0 mmol, 2.0 equiv). The mixture was stirred at 0 °C, and added slowly the solution of **S2b** (0.31 g, 3.0 mmol, 1.5 equiv) in DCM (5 mL) under argon atmosphere. The resulting solution was stirred at room temperature for 8 h, followed by the addition of H₂O (50 mL) to quench excess acyl chloride, and extracted with DCM (15 mL × 3). The combined organic layer was washed with brine (15 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (10:1, v/v) as the eluent to give product **1**y.

N-Methyl-N,2-diphenylacrylamide (1y)



General procedure 8 was followed to obtain 1y (0.26 g, 1.22 mmol, 66%) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.24 – 6.87 (m, 9H, Ar-H), 5.47 (s, 1H, =CH₂), 5.37 (s, 1H, =CH₂), 3.40 (s, 3H, N-CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.6, 145.8, 128.9, 128.3, 128.0, 127.9, 127.0, 126.95, 126.93, 126.91, 126.86, 126.1, 37.5.

N-(4,6-Dimethylpyrimidin-2-yl)-*N*-phenylmethacrylamide (1z)



General procedure 4 (A) was followed to obtain **1z** (0.31g,1.16 mmol, 58%) as a yellow solid. **Mp** 152–153 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.35 (m, 2H, Ar-H), 7.28 – 7.24 (m, 1H, Ar-H), 7.18 (d, *J* = 7.6 Hz, 2H, Ar-H), 6.80 (s, 1H, Ar-H), 5.19 (s, 1H, =CH₂), 5.05 (s, 1H, =CH₂), 2.39 (s, 6H, Ar-H), 2.04 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.6, 168.3, 162.1, 143.3, 141.2, 129.0, 127.2, 126.7, 117.7, 117.0, 77.4, 77.1, 76.7, 23.8, 19.7. **HRMS** (ESI) calcd for C₁₆H₁₈N₃O [M+H]⁺ 268.1444, found 268.1449.

2.2.6 General Procedure 9 for Preparation of Substrates 1cc.



To a 50 mL round-bottom flask was added the solution of **S6b** (0.5 g, 3.0 mmol, 1.0 equiv) in MeOH (25 mL). The mixture was stirred at 0 $^{\circ}$ C, and added slowly thionylchloride (0.71 g, 6.0 mol, 5.0 equiv), refluxed under stirring for 4 h. The solvent was removed under reduced pressure to get the product **1aa** (0.52 g).

To a 20 mL Schlenk tube was added **1aa** (0.36 g, 2.0 mmol, 1.0 equiv), diphenyliodonium bromide **S7a** (0.79 g, 2.2 mmol, 1.1 equiv), silver nitrate (0.37 g, 2.2 mmol, 1.1 equiv) and CuBr (2.87 mg, 0.02 mmol, 1.0 %mol) and MeCN (10 mL) under argon atmosphere. The mixture was refluxed under stirring for 3 h, followed by the addition of H₂O (50 mL), and extracted with DCM (15 mL \times 3). The combined organic layer was washed with brine (15 mL \times 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (8:1, v/v) as the eluent to give product **1bb**.

To a 50 mL round-bottom flask was added the solution of **1bb** (0.51 g, 2.0 mmol, 1.0 equiv) in benzene (15 mL) and K_2CO_3 (0.42 g, 3.0 mmol, 1.5 equiv). Then the reaction mixture was added slowly with acryloyl chloride **S2a** (0.31 g, 3.0 mmol, 1.5 equiv) under argon atmosphere, refluxed under stirring for 24 h. After cooling to room temperature, the reaction mixture was quenched with water (50 mL) and extracted with DCM (15 mL × 3). The combined organic layer was washed with brine

(15 mL \times 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (5:1, v/v) as the eluent to give product **1cc**.

(S)-Methyl 2-amino-3-phenylpropanoate (1aa)



General procedure 9 was followed to obtain 1aa (0.52 g, 2.88 mmol, 96 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.33 – 7.18 (m, 5H, Ar-H), 3.76 – 3.73 (m, 1H, CO-CH), 3.72 (s, 3H, O-CH₃), 3.09 (dd, *J* = 13.5, 5.2 Hz, 1H, Ar-CH₂), 2.86 (dd, *J* = 13.5, 7.9 Hz, 1H, Ar-CH₂), 1.48 (s, 2H, NH₂).

(S)-Methyl 3-phenyl-2-(phenylamino)propanoate (1bb)



General procedure 9 was followed to obtain **1bb** (0.42 g, 1.66 mmol, 83 %) as a yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.24 (m, 3H, Ar-H), 7.22 – 7.13 (m, 4H, Ar-H), 6.76 – 6.72 (m, 1H, Ar-H), 6.60 (d, *J* = 8.4 Hz, 2H, Ar-H), 4.37 (t, *J* = 6.2 Hz, 1H, CH), 4.17 (dr, 1H, NH), 3.66 (s, 3H, O-CH₃), 3.13 (qd, *J* = 13.6, 6.2 Hz, 2H, CH₂).

(S)-Methyl 3-phenyl-2-(N-phenylmethacrylamido)propanoate (1cc)



General procedure 9 was followed to obtain 1bb (0.60 g, 1.84 mmol, 92 %) as a yellow solid. Mp 79–80 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.27 (m, 3H, Ar-H), 7.21 – 7.12 (m, 5H, Ar-H), 6.61 – 6.57 (m, 2H, Ar-H), 5.00 – 4.95 (s, 1H, =CH₂), 4.89 (s, 1H, =CH₂), 4.56 (dd, *J* = 10.5, 5.3 Hz, 1H, CH), 3.80 (s, 3H, O-CH₃), 3.52 – 3.39 (m, 2H, CH₂), 1.67 (s, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 171.0, 140.4, 138.3, 129.6, 128.9, 128.6, 127.6, 127.3, 126.8, 119.9, 65.4, 52.5, 34.8, 19.9. **HRMS** (ESI) calcd for C₂₀H₂₂NO₃ [M+H]⁺ 324.1594, found 324.1598.

3. Investigation of the Key Reaction Parameters.





^a Reaction conditions: alkene 1a (0.3 mmol), 2a (0.9 mmol), base (0.9 mmol), photocatalyst (2.0 mol%), MeCN (2.0 mL) under 25 W blue LED irradiation (λ max = 480 nm) for 36 h. Yields of isolated products. ^b Reaction conditions: alkene 1a (0.3 mmol), 2a (0.75 mmol), base (0.75 mmol), photocatalyst (2.0 mol%), MeCN (2.0 mL) under 25 W blue LED irradiation (λ max = 480 nm) for 24 h. Yields of isolated products.

Table 52. Sereening of solvent				
entry	solvent	3a yield (%)	4a yield (%)	
1ª	MeCN	92	0	
2ª	toluene	≤5	0	
3 ^a	DMF	56	0	
4 ^a	DCM	32	0	
5 ^a	THF	≤5	0	
6 ^b	MeCN	0	94	

Table S2. Screening of solvent

^a Reaction conditions: alkene 1a (0.3 mmol), 2a (0.9 mmol), Na₂CO₃ (0.9 mmol), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (2.0 mol%), solvent (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm) for 36 h. Yields of isolated products. ^b Reaction conditions: alkene 1a (0.3 mmol), 2a (0.75 mmol), NaOAc (0.75 mmol), Ir(btp)₂Ala (2.0 mol%), solvent (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm) for 36 h. Yields of isolated products.

entry	ratio of 1a and 2a	base	3a yield (%)	4a yield (%)
1 ^a	1:1.5	1.5 equiv	61	0
2ª	1:2.0	2.0 equiv	74	0
3 ^a	1:2.5	2.5 equiv	84	0
4 ^a	1:3.0	3.0 equiv	92	0
5 ^b	1:1.5	1.5 equiv	0	50
6 ^b	1:2.0	2.0 equiv	0	77
7 ^b	1:2.5	2.5 equiv	0	94

Table S3. Screening of ratio of 1a and 2a/base

^a Reaction conditions: alkene 1a (0.3 mmol), 2a, Na₂CO₃, Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (2.0 mol%), MeCN (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm) for 36 h. Yields of isolated products. ^b Reaction conditions: alkene 1a (0.3 mmol), 2a (0.75 mmol), NaOAc, Ir(btp)₂Ala (2.0 mol%), MeCN (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm) for 36 h. Yields of isolated products.

entry	time	3a yield (%)	4a yield (%)
1 ^a	12 h	46	0
2ª	24 h	70	0
3 ^a	36 h	92	0
4 ^a	48 h	89	0
5 ^b	12 h	0	87
6 ^b	24 h	0	94
7 ^b	36 h	0	94

Table S4. Screening of time

^a Reaction conditions: alkene 1a (0.3 mmol), 2a (0.9 mmol), Na₂CO₃ (0.9 mmol), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (2.0 mol%), MeCN (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm). Yields of isolated products. ^b Reaction conditions: alkene 1a (0.3 mmol), 2a (0.75 mmol), NaOAc (0.75 mmol), Ir(btp)₂Ala (2.0 mol%), MeCN (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm). Yields of isolated products.

Table S4. Screening of Light Source

entry	light source	3a yield (%)	4a yield (%)
1^{a}	5 W blue	44	0
2ª	10 W blue	48	0
3 ^a	25 W blue	92	0
4 ^b	25 W blue	0	94

^a Reaction conditions: alkene 1a (0.3 mmol), 2a (0.9 mmol), Na₂CO₃ (0.9 mmol), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (2.0 mol%), MeCN (2.0 mL) under blue LED irradiation (λ max = 480 nm) for 36 h. Yields of isolated products. ^b Reaction conditions: alkene 1a (0.3 mmol), 2a (0.75 mmol), NaOAc (0.75 mmol), Ir(btp)₂Ala (2.0 mol%), MeCN (2.0 mL) under 25W blue LED irradiation (λ max = 480 nm) for 24 h. Yields of isolated products.

4. Investigation of the mechamism.

4.1 General Procedure 10 for Mechanistic Study (a)



Under argon atmosphere, to a 10 mL Schlenk tube was added **1a** (52.6 mg, 0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride (129.2 mg, 0.9 mmol, 3.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv), TEMPO (117.18 mg, 0.75 mmol, 2.5 equiv), $Ir\{dF(CF_3)ppy\}_2(dtbbpy)PF_6$ (6.7 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 36 hours.

4.2 General Procedure 11 for Mechanistic Study (b)



Under argon atmosphere, to a 10 mL Schlenk tube was added **1a** (52.6 mg, 0.3 mmol, 1.0 equiv), NaOAc (61.5 mg, 0.75 mmol, 2.5 equiv), dimethylsulfamoyl chloride (0.75 mmol, 2.5 equiv), TEMPO (117.18 mg, 0.75 mmol, 2.5 equiv), $Ir(btp)_2Ala$ (4.5 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 24 hours. 4.3 General Procedure 12 for Mechanistic Study (c)



Under argon atmosphere, to a 10 mL Schlenk tube was added **S7a** (54.1 mmol, 0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride (129.2 mg, 0.9 mmol, 3.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (6.7 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 36 hours. The solution was concentrated in vacuo. The product was determined by HRMS (ESI) calcd for

C₁₄H₁₁O₃S [M-Na]⁻ 259.0434, found 259.0433.

4.4 General Procedure 13 for Mechanistic Study (d)



Under argon atmosphere, to a 10 mL Schlenk tube was added **S7a** (54.1 mg, 0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride (107.7 mg, 0.75 mmol, 2.5 equiv), NaOAc (61.5 mg, 0.75 mmol, 2.5 equiv), Ir(btp)₂Ala (4.5 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 24 hours, followed by the addition of H₂O (20 mL), and extracted with DCM (10 mL \times 3). The combined organic layer was washed with brine (10 mL \times 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (8:1, v/v) as the eluent to give product **6**.

N,*N*-Dimethyl-2,2-diphenylethene-1-sulfonamide (7)



General procedure 13 was followed to obtain 7 (49.1 mg, 0.17 mmol, 57 %) as a white solid. Mp 141–142 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.45 – 7.38 (m, 4H, Ar-H), 7.38 – 7.30 (m, 5H, Ar-H), 7.26–7.24 (m, 1H, Ar-H), 6.66 (s, 1H, CH), 2.67 (s, 6H, N-CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 154.5, 139.8, 136.6, 130.0, 129.7, 128.9, 128.6, 128.2, 128.0, 122.3, 37.1. HRMS (ESI) calcd for C₁₆H₁₈NO₂S [M+H]⁺ 288.1053, found 288.1059.

4.5 General Procedure 14 for Mechanistic Study (e)



Under argon atmosphere, to a 10 mL Schlenk tube was added **4a** (84.7 mg, 0.3 mmol, 1.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv), NaOH (36.0 mg, 0.9 mmol, 3.0 equiv), $Ir\{dF(CF_3)ppy\}_2(dtbbpy)PF_6$ (6.7 mg, 0.06 mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 36 hours.

4.6 General Procedure 15 for Mechanistic Study (f)



Under argon atmosphere, to a 10 mL Schlenk tube was added **1** (52.6 mg, 0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride (129.2 mg, 0.9 mmol, 3.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (6.7 mg, 0.06 mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 36 hours. Benzoyl chloride (210.84 mg, 1.5 mmol, 5.0 equiv) was added to the reaction mixture. The resulting solution was stirred at room temperature for 12 h. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (20:1, v/v) as the eluent to give **8** and **9**.

N,N-Dimethylbenzamide (8)



General procedure 15 was followed to obtain 8 (20.6 mg, 0.14 mmol, 46 %) as a white solid. Mp 41–43 °C.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.44 – 7.36 (m, 5H, Ar-H), 3.11 (s, 3H, N-CH₃), 2.97 (s, 3H, N-CH₃).

N-Methylbenzamide (9)



General procedure 15 was followed to obtain 8 (10.9 mg, 0.08 mmol, 27 %) as a white solid. Mp 78–79 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.77 – 7.75 (m, 2H, Ar-H), 7.51 – 7.47 (m, 1H, Ar-H), 7.45 – 7.39 (m, 2H, Ar-H), 3.02 (d, J = 4.9 Hz, 3H, N-CH₃).

4.7 General Procedure 16 for Mechanistic Study (g)



Under argon atmosphere, to a 10 mL Schlenk tube was added dimethylsulfamoyl chloride (129.2 mg, 0.9 mmol, 3.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv) and 2 mL CD₃CN. The reaction mixture was stirred at room temperature for 12 hours. The product was determined by ¹H NMR spectrum, ¹³C NMR spectrum and **HRMS** (ESI) calcd for C₂H₆NO₂S [M]⁺ 108.0114, found 108.0111.

4.8 General Procedure 17 for Mechanistic Study (h)



Under argon atmosphere, to a 10 mL Schlenk tube was added dimethylsulfamoyl chloride (0.75 mmol, 2.5 equiv), NaOAc (61.5 mg, 0.75 mmol, 2.5 equiv) and 2 mL MeCN. The reaction mixtue was stirred at room temperature for 24 hours. **1a** (52.6 mg, 0.3 mmol, 1.0 equiv) and Ir(btp)₂Ala (4.5 mg, 0.06mmol, 2.0 mol%) were added

to the reaction mixture. The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 24 hours.



4.9 Scheme S1: Proposed Mechanism of **3t**

Under argon atmosphere, Six standard reaction mixtures in 10 mL Schlenk tubes were charged with **1a** (52.5mg, 0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride (129.2 mg, 0.9 mmol, 3.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv),

Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆ (6.7 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The mixtures were then stirred rapidly and irradiated with a 25 W Blue LED (approximately 2 cm away from the light source) at room temperature. After 3 h, the Blue LED was turned off, and one tube was removed from the irradiation setup for analysis. The remaining five tubes were stirred in the absence of light for an additional 3 h. Then, one tube was removed for analysis, and the Blue LED was turned back on to irradiate the remaining four reaction mixtures. After an additional 3 h of irradiation, the Blue LED was turned off, and one tube was removed for analysis. The remaining three tubes were stirred in the absence of light for an additional 3 h. Then, a tube was removed for analysis, and the Blue LED was turned back on to irradiate the remaining three. After 3 h, the Blue LED was turned off, and one tube was turned back on to irradiate the remaining three tubes were stirred in the absence of light for an additional 3 h. Then, a tube was removed for analysis, and the Blue LED was turned off, and one tube was turned off, and one tube was removed for analysis. The last tube was turned back on to irradiate the remaining three tubes. After 3 h, the Blue LED was turned off, and one tube was removed for analysis. The last tube was stirred in the absence of light for an additional 3 h, and then it was analyzed. The yield was determined by flash chromatography on a silica gel using DCM and methanol (10:1, v/v).



Under argon atmosphere, Six standard reaction mixtures in 10 mL Schlenk tubes were charged with **1a** (52.5mg, 0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride

(107.7 mg, 0.75 mmol, 2.5 equiv), NaOAc (61.5 mg, 0.75 mmol, 2.5 equiv), Ir(btp)₂Ala (4.5 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The mixtures were then stirred rapidly and irradiated with a 25 W Blue LED (approximately 2 cm away from the light source) at room temperature. After 3 h, the Blue LED was turned off, and one tube was removed from the irradiation setup for analysis. The remaining five tubes were stirred in the absence of light for an additional 3 h. Then, one tube was removed for analysis, and the Blue LED was turned back on to irradiate the remaining four reaction mixtures. After an additional 3 h of irradiation, the Blue LED was turned off, and one tube was removed for analysis. The remaining three tubes were stirred in the absence of light for analysis. The remaining three tubes were stirred in the absence of light for analysis. The remaining three tubes were stirred in the absence of light for an additional 3 h. Then, a tube was removed for analysis, and the Blue LED was turned back on to irradiate the remaining three tubes were stirred in the absence of light for an additional 3 h. Then, a tube was removed for analysis. The last tube was stirred in the absence of light for an additional 3 h, and then it was analyzed. The yield was determined by ¹H NMR with mesitylene as an internal standard.

4.12 Stern-Volmer measurements

Emission intensities were recorded using a F27000 (Hitachi Limited) luminescence spectrophotometer. All $Ir\{dF(CF_3)ppy\}_2(dtbbpy)PF_6$ and $Ir(btp)_2Ala$ solutions were excited at 350 nm and the emission intensity was collected at 475 nm. In a typical experiment, to a 1 × 10⁻⁵ mol/L solution of $Ir\{dF(CF_3)ppy\}_2(dtbbpy)PF_6$ or $Ir(btp)_2Ala$ in acetonitrile was added the appropriate amount of a quencher in a screw-top quartz cuvette. After degassing the sample with a stream of argon for 10 minutes, the emission of the sample was collected.



 $Ir{dF(CF_3)ppy}_2(dtbbpy)PF_6$ emission quenching with 2a or 2a + Na₂CO₃

 $Ir(btp)_2Ala$ emission quenching with 2a or 2a + NaOAc

5. Experimental Procedures and Product Characterization.

5.1 General Procedure 18 for Sulfonation of Substrates 1.



Under argon atmosphere, to a 10 mL Schlenk tube was added 1 (0.3 mmol, 1.0 equiv), dimethylsulfamoyl chloride (129.2 mg, 0.9 mmol, 3.0 equiv), Na₂CO₃ (95.4 mg, 0.9 mmol, 3.0 equiv), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆(6.7 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN, The reaction mixture was stirred at room temperature under 25 W blue LED irradiation for 36 hours, and concentrated. The residue was purified by flash chromatography on a silica gel using DCM and methanol (10:1, v/v) as the eluent to give **3**.

Sodium (1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3a)



General procedure 18 was followed to obtain 3a (76.6 mg, 0.28 mmol, 92 %) as a colorless oil.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.55 (d, J = 7.3 Hz, 1H, Ar-H), 7.22 – 7.18 (m, 1H, Ar-H), 6.97 – 6.91 (m, 2H, Ar-H), 3.08 (s, 3H, N-CH₃), 3.04 (d, J = 13.9 Hz, 1H, CH₂), 2.85 (d, J = 13.9 Hz, 1H, CH₂), 1.28 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.7, 143.3, 133.7, 127.5, 125.6, 121.8, 108.2, 57.3, 46.5, 26.5, 24.4. **HRMS** (ESI) calcd for C₁₁H₁₂NO₄S [M-Na]⁻ 254.0493, found 254.0497.

Sodium (5-fluoro-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3b)



General procedure 18 was followed to obtain 3b (79.7 mg, 0.27 mmol, 90 %) as a colorless oil.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.44 (d, J = 7.7 Hz, 1H, Ar-H), 7.03 (d, J = 8.0 Hz, 1H, Ar-H), 6.91 (dd, J = 7.7, 4.1 Hz, 1H, Ar-H), 3.08 (s, 3H, N-CH₃), 3.08 (d, J = 13.8 Hz, 1H, CH₂), 2.88 (d, J = 13.8 Hz, 1H, CH₂), 1.29 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.0, 159.2, 156.9, 139.2, 135.0 (d, J = 8.0 Hz, 1C), 113.29 (d, J = 4.0 Hz, 1C), 108.2 (d, J = 8.0 Hz, 1C), 56.5, 46.4, 26.2, 23.7. **HRMS** (ESI) calcd for C₁₁H₁₁FNO₄S [M-Na]⁻ 272.0398, found 272.0391.

Sodium (5-chloro-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3c)



General procedure 18 was followed to obtain 3c (82.3 mg, 0.26 mmol, 88 %) as a white solid. Mp 248–249 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.60 (d, J = 2.0 Hz, 1H, Ar-H), 7.25 (dd, J = 8.3, 2.1 Hz, 1H, Ar-H), 6.94 (d, J = 8.3 Hz, 1H, Ar-H), 3.09 (d, J = 13.9 Hz, 1H, CH₂), 3.07 (s, 3H, N-CH₃), 2.87 (d, J = 13.9 Hz, 1H, CH₂), 1.27 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 178.9, 141.9, 135.2, 126.8, 125.4, 109.0, 56.6, 46.2, 26.1, 23.8. **HRMS** (ESI) calcd for C₁₁H₁₁ClNO4S [M-Na]⁻ 288.0103, found 288.0109.

Sodium (5-bromo-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3d)



General procedure 18 was followed to obtain 3d (95.1 mg, 0.27 mmol, 89 %) as a white solid. Mp 285–287 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.72 (d, J = 1.8 Hz, 1H, Ar-H), 7.37 (dd, J = 8.3, 1.8 Hz, 1H, Ar-H), 6.89 (d, J = 8.3 Hz, 1H, Ar-H), 3.06 (s, 3H, N-CH₃), 3.05 (d, J = 13.8 Hz, 1H, CH₂), 2.85 (d, J = 13.8 Hz, 1H, CH₂), 1.27 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 178.7, 142.4, 135.6, 129.7, 128.0, 113.3, 109.6, 56.7, 46.2, 26.1, 23.8. **HRMS** (ESI) calcd for C₁₁H₁₁BrNO₄S [M-Na]⁻ 331.9598, found 331.9595. **Sodium (5-iodo-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3e)**



General procedure 18 was followed to obtain **3e** (101.6 mg, 0.25 mmol, 84 %) as a white solid. **Mp** 191–193 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.85 (d, J = 1.7 Hz, 1H, Ar-H), 7.54 (dd, J = 8.1, 1.7 Hz, 1H, Ar-H), 6.79 (d, J = 8.2 Hz, 1H, Ar-H), 3.18 (d, J = 13.9 Hz, 1H, CH₂), 3.06 (s, 3H, N-CH₃), 2.88 (d, J = 13.9 Hz, 1H, CH₂), 1.26 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 178.6, 142.9, 135.9, 135.6, 133.4, 110.2, 84.5, 56.7, 46.1, 26.0, 23.9. **HRMS** (ESI) calcd for C₁₁H₁₁INO₄S [M-Na]⁻ 379.9459, found 379.9464. **Sodium (1,3,5-trimethyl-2-oxoindolin-3-yl)methanesulfonate (3f)**



General procedure 18 was followed to obtain 3f (78.7 mg, 0.27 mmol, 90 %) as a colorless oil.

¹**H** NMR (400 MHz, DMSO-*d6*) δ 7.40 (s, 1H, Ar-H), 7.00 (d, J = 7.7 Hz, 1H, Ar-H), 6.80 (d, J = 7.9 Hz, 1H, Ar-H), 3.06 (s, 3H, N-CH₃), 3.04 (d, J = 13.8 Hz, 1H, CH₂), 2.82 (d, J = 13.8 Hz, 1H, CH₂), 2.26 (s, 3H, Ar-CH₃), 1.27 (s, 3H, CH₃). ¹³C NMR (100 MHz, DMSO-*d6*) δ 179.7, 141.0, 133.8, 130.3, 127.7, 126.4, 107.9, 57.3, 46.5, 26.5, 24.4, 21.4. **HRMS** (ESI) calcd for C₁₂H₁₄NO₄S [M-Na]⁻ 268.0649, found 268.0641.

Sodium (5-methoxy-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3g)



General procedure 18 was followed to obtain 3g (84.8 mg, 0.28 mmol, 92 %) as a colorless oil.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.30 (d, J = 2.5 Hz, 1H, Ar-H), 6.82 (d, J = 8.4 Hz, 1H, Ar-H), 6.76 (dd, J = 8.4, 2.6 Hz, 1H, Ar-H), 3.70 (s, 3H, O-CH₃), 3.05 (s, 3H, N-CH₃), 3.03 (d, J = 13.9 Hz, 1H, CH₂), 2.78 (d, J = 13.9 Hz, 1H, CH₂), 1.28 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.4, 155.3, 136.8, 135.1, 113.5, 111.8, 108.3, 57.1, 55.8, 46.9, 26.6, 24.2. **HRMS** (ESI) calcd for C₁₂H₁₄NO₅S [M-Na]⁻284.0598, found 284.0596.

Sodium (5-cyano-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3h)



General procedure 18 was followed to obtain **3h** (44.4 mg, 0.15 mmol, 49 %) as a white solid. **Mp** 217–219 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.86 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H, Ar-H), 7.11 (d, J = 8.1 Hz, 1H, Ar-H), 3.17 (s, 1H, Ar-H), 3.15 (d, J = 13.8 Hz, 1H, CH₂), 3.12 (s, 3H, N-CH₃), 2.98 (d, J = 13.8 Hz, 1H, CH₂), 1.26 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.3, 147.4, 133.9, 132.5, 128.4, 120.0, 108.6, 102.9, 56.8, 45.7, 26.3, 24.0. **HRMS** (ESI) calcd for C₁₂H₁₁N₂O₄S [M-Na]⁻ 279.0445, found 279.0441.

Sodium (5-(methoxycarbonyl)-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3i)



General procedure 18 was followed to obtain 3i (67.4 mg, 0.20 mmol, 67 %) as a white solid. Mp > 300 °C.
¹**H NMR** (400 MHz, DMSO-*d6*) δ 8.05 (d, J = 1.6 Hz, 1H, Ar-H), 7.87 (dd, J = 8.2, 1.8 Hz, 1H, Ar-H), 7.03 (d, J = 8.2 Hz, 1H, Ar-H), 3.82 (s, 3H, O-CH₃), 3.15 (d, J = 13.8 Hz, 1H, CH₂), 3.11 (s, 3H, N-CH₃), 2.95 (d, J = 13.8 Hz, 1H, CH₂), 1.26 (s, 3H, CH₃). ¹³C **NMR** (100 MHz, DMSO-*d6*) δ 180.1, 167.1, 148.1, 133.6, 130.1, 126.3, 122.9, 108.1, 57.5, 52.2, 46.3, 26.7, 25.5, 24.7. **HRMS** (ESI) calcd for C₁₃H₁₄NO₆S [M-Na]⁻ 312.0547, found 312.0556.

Sodium (5,7-difluoro-1,3-dimethyl-2-oxoindolin-3-yl)methanesulfonate (3j)



General procedure 18 was followed to obtain **3j** (33.8 mg, 0.11 mmol, 36 %) as a white solid. **Mp** 163–164 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 6.77 (dd, J = 9.3, 2.0 Hz, 1H, Ar-H), 6.63 (td, J = 10.4, 2.1 Hz, 1H, Ar-H), 3.06 (d, J = 4.9 Hz, 2H, CH₂), 3.04 (s, 3H, N-CH₃), 1.20 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.2, 104.2, 97.0, 96.7, 96.4, 93.8 (d, J = 3.3 Hz, 1C), 93.6 (d, J = 2.3 Hz, 1C), 57.4, 45.5, 27.1, 24.1. **HRMS** (ESI) calcd for C₁₁H₁₀F₂NO₄S [M-Na]⁻ 290.0304, found 290.0307.

Sodium (1,3-dimethyl-2-oxo-7-phenylindolin-3-yl)methanesulfonate (3k)



General procedure 18 was followed to obtain 3k (94.3 mg, 0.27 mmol, 89 %) as a white solid. Mp 172–174 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.58 – 7.56 (m, 1H, Ar-H), 7.44 – 7.41 (m, 2H, Ar-H), 7.39 – 7.37 (m, 3H, Ar-H), 6.99 (d, J = 4.4 Hz, 2H, Ar-H), 3.10 (d, J = 13.8 Hz, 1H, CH₂), 2.95 (d, J = 13.8 Hz, 1H, CH₂), 2.58 (s, 3H, N-CH₃), 1.33 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 181.0, 140.3, 139.6, 134.7, 131.4, 130.3, 130.2, 128.2, 127.8, 124.8, 124.4, 121.3, 118.0, 57.6, 45.8, 30.6, 24.8. **HRMS** (ESI) calcd for C₁₇H₁₆NO₄S [M-Na]⁻ 330.0806, found 330.0809. Sodium

(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[g]indol-3-yl)methanesulfonate (3l)



General procedure 18 was followed to obtain 31 (70.7 mg, 0.22 mmol, 72 %) as a white solid. Mp > 300 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.68 (d, J = 7.8 Hz, 1H, Ar-H), 7.54 (d, J = 7.1 Hz, 1H, Ar-H), 7.51 – 7.45 (m, 2H, Ar-H), 7.40 (d, J = 7.9 Hz, 1H, Ar-H), 6.95 (d, J = 7.5 Hz, 1H, Ar-H), 3.69 (d, J = 13.6 Hz, 1H, CH₂), 3.37 (s, 3H, N-CH₃), 3.31 (d, J = 13.6 Hz, 1H, CH₂), 1.46 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 172.5, 137.5, 137.4, 133.2, 126.9, 126.4, 125.4, 124.8, 121.9, 119.6, 108.1, 62.3, 45.9, 33.6, 29.8. **HRMS** (ESI) calcd for C₁₅H₁₄NO₄S [M-Na]⁻ 304.0649, found 304.0657.

Sodium

(1,3-Dimethyl-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-b]pyridin-3-yl)methanesulfonat e (3m)



General procedure 18 was followed to obtain **3m** (44.2 mg, 0.16 mmol, 53 %) as a white solid. **Mp** 163–164 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 8.07 (dd, J = 5.2, 1.6 Hz, 1H, Ar-H), 7.77 (dd, J = 7.2, 1.5 Hz, 1H, Ar-H), 6.96 – 6.93 (m, 1H, Ar-H), 3.10 (s, 3H, N-CH₃), 3.06 (d, J = 13.8 Hz, 1H, CH₂), 2.95 (d, J = 13.8 Hz, 1H, CH₂), 1.28 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.6, 156.6, 146.0, 133.1, 127.9, 117.9, 56.9, 46.1, 25.5, 24.0. **HRMS** (ESI) calcd for C₁₀H₁₁N₂O₄S [M-Na]⁻ 255.0445, found 255.0441.

Sodium

(1,3-dimethyl-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-b]quinolin-3-yl)methanesulfonat e (3n)



General procedure 18 was followed to obtain 3n (56.1 mg, 0.17 mmol, 57 %) as a Mp 133–134 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 8.16 (s, 1H, Ar-H), 7.82 (d, J = 8.4 Hz, 2H, Ar-H), 7.63 – 7.60 (m, 1H, Ar-H), 7.42 – 7.38 (m, 1H, Ar-H), 3.20 (s, 3H, N-CH₃), 3.17 (d, J = 13.8 Hz, 1H, CH₂), 3.11 (d, J = 13.8 Hz, 1H, CH₂), 1.35 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.6, 156.9, 146.6, 131.7, 129.2, 128.9, 128.7, 127.3, 126.5, 124.2, 57.5, 45.6, 25.9, 24.7. **HRMS** (ESI) calcd for C₁₄H₁₃N₂O₄S [M-Na]⁻ 305.0602, found 305.0609.

Sodium (3-methyl-2-oxo-1-phenylindolin-3-yl)methanesulfonate (30)



General procedure 18 was followed to obtain **30** (88.6 mg, 0.26 mmol, 87 %) as a white solid. **Mp** 232–234 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.56 – 7.50 (m, 3H, Ar-H), 7.45 – 7.40 (m, 3H, Ar-H), 7.14 – 7.10 (m, 1H, Ar-H), 7.00 – 6.97 (m, 1H, Ar-H), 6.62 (d, *J* = 7.8 Hz, 1H, Ar-H), 3.18 (d, *J* = 13.8 Hz, 1H, CH₂), 3.10 (d, *J* = 13.8 Hz, 1H, CH₂), 1.35 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.4, 143.4, 135.7, 133.2, 129.7, 128.1, 127.5, 127.4, 125.8, 122.1, 108.5, 58.0, 46.5, 25.4. **HRMS** (ESI) calcd for C₁₆H₁₄NO₄S [M-Na]⁻ 316.0649, found 316.0641.

Sodium (1-benzyl-3-methyl-2-oxoindolin-3-yl)methanesulfonate (3p)



General procedure 18 was followed to obtain 3p (85.9 mg, 0.24 mmol, 81 %) as a white solid. Mp 253–255 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.57 (d, J = 7.3 Hz, 1H, Ar-H), 7.41 – 7.28 (m, 4H, Ar-H), 7.26 – 7.22 (m, 1H, Ar-H), 7.10 – 7.07 (m, 1H, Ar-H), 6.95 – 6.91 (m, 1H, Ar-H), 6.72 (d, J = 7.7 Hz, 1H, Ar-H), 4.87 (q, J = 8.7 Hz, 2H, N-CH₂), 3.17 (d, J = 13.9 Hz, 1H, CH₂), 2.98 (d, J = 13.9 Hz, 1H, CH₂), 1.35 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.9, 142.2, 137.2, 133.6, 129.0, 127.6, 127.4, 125.8, 121.9, 108.9, 57.2, 46.6, 43.1, 25.0. **HRMS** (ESI) calcd for C₁₇H₁₆NO₄S [M-Na]⁻ 330.0806, found 330.0809.

Sodium (1-(2-ethoxy-2-oxoethyl)-3-methyl-2-oxoindolin-3-yl)methanesulfonate (3q)



General procedure 18 was followed to obtain 3q (91.2 mg, 0.26 mmol, 87 %) as a white solid. Mp 248–250 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.65 (d, J = 7.3 Hz, 1H), 7.19 – 7.15 (m, 1H), 6.98 – 6.95 (m, 1H), 6.92 (d, J = 7.8 Hz, 1H), 4.50 (q, J = 17.7 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.05 (d, J = 13.9 Hz, 1H), 2.80 (d, J = 13.9 Hz, 1H), 1.35 (s, 3H), 1.19 (t, J = 7.1 Hz, 3H). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 180.0, 168.5, 142.1, 133.5, 127.5, 126.1, 122.0, 108.4, 61.5, 56.9, 46.5, 41.5, 24.0, 14.5. **HRMS** (ESI) calcd for C₁₄H₁₆NO₆S [M-Na]⁻ 326.0704, found 326.0709.

Sodium

(1-methyl-2-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)methanesul fonate (3r)



General procedure 18 was followed to obtain **3r** (76.4 mg, 0.25 mmol, 84 %) as a white solid. **Mp** 120–121 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.41 (d, *J* = 7.4 Hz, 1H, Ar-H), 6.95 (d, *J* = 7.6 Hz, 1H, Ar-H), 6.83 – 6.80 (m, 1H, Ar-H), 3.60 – 3.52 (m, 2H, N-CH₂), 2.99 (d, *J* = 13.8

Hz, 1H, CH₂), 2.77 (d, J = 13.8 Hz, 1H, CH₂), 2.71 (t, J = 6.0 Hz, 2H, Ar-H), 1.93 – 1.84 (m, 2H, NCH₂-CH₂), 1.30 (s, 3H, CH₃). ¹³C NMR (100 MHz, DMSO-*d6*) δ 178.5, 139.0, 132.4, 126.3, 123.9, 121.1, 119.5, 57.1, 47.7, 38.8, 24.6, 23.7, 21.2. HRMS (ESI) calcd for C₁₃H₁₄NO₄S [M-Na]⁻ 280.0649, found 280.0646.

Sodium

(7-methyl-6-oxo-6,7,11,12-tetrahydrobenzo[6,7]azepino[3,2,1-hi]indol-7-yl)metha nesulfonate (3s)



General procedure 18 was followed to obtain **3s** (87.7 mg, 0.24 mmol, 80 %) as a white solid. **Mp** 216–217 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.83 (d, J = 7.7 Hz, 1H, Ar-H), 7.27 – 7.23 (m, 2H, Ar-H), 7.23 – 7.12 (m, 2H, Ar-H), 6.97 (d, J = 7.5 Hz, 1H, Ar-H), 6.92 – 6.88 (m, 1H, Ar-H), 3.21 (d, J = 5.8 Hz, 2H, Ar-CH₂), 3.06 – 2.93 (m, 3H, Ar-CH₂, CH₂), 2.89 –2.82 (m, 1H, CH₂), 1.28 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 180.1, 140.2, 137.0, 133.7, 129.3, 129.2, 126.2, 124.9, 122.9, 121.7, 58.5, 46.1, 33.8, 33.4, 26.7. **HRMS** (ESI) calcd for C₁₈H₁₆NO₄S [M-Na]⁻ 342.0806, found 342.0801.

Sodium 2-methyl-3-oxo-3-(phenylamino)-2-(p-tolyl)propane-1-sulfonate (3t)



General procedure 18 was followed to obtain 3t (46.9 mg, 0.13 mmol, 44 %) as a white solid. Mp > 300 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 9.88 (s, 1H, NH), 7.56 (d, J = 8.0 Hz, 2H, Ar-H), 7.29 – 7.19 (m, 4H, Ar-H), 7.09 (d, J = 8.2 Hz, 2H, Ar-H), 7.02 – 6.98 (m, 1H, Ar-H), 3.69 (d, J = 14.4 Hz, 1H, CH₂), 2.96 (d, J = 14.4 Hz, 1H, CH₂), 2.25 (s, 3H, Ar-CH₃), 1.72 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 174.0, 143.5, 140.1, 135.5, 129.1, 128.7, 126.3, 123.4, 120.5, 59.7, 50.2, 24.1, 21.0. **HRMS** (ESI) calcd for C₁₇H₁₈NO₄S [M-Na]⁻ 332.0962, found 332.0968.

Sodium (1-methyl-2-oxo-3-phenylindolin-3-yl)methanesulfonate (3u)



General procedure 18 was followed to obtain **3u** (84.5 mg, 0.25 mmol, 83 %) as a white solid. **Mp** 214–216 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.31 (d, J = 7.2 Hz, 1H, Ar-H), 7.25 – 7.19 (m, 6H, Ar-H), 6.99 – 6.94 (m, 2H, Ar-H), 3.59 (d, J = 13.7 Hz, 1H, CH₂), 3.51 (d, J = 13.7 Hz, 1H, CH₂), 3.08 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 177.3, 141.2, 130.8, 128.2, 127.4, 126.8, 126.4, 126.4, 121.1, 107.9, 57.2, 54.0, 26.3. **HRMS** (ESI) calcd for C₁₆H₁₄NO₄S [M-Na]⁻ 316.0649, found 316.0653.

Sodium

(5,7-dimethyl-6-oxo-6,7-dihydro-5H-[1,3]dioxolo[4,5-f]indol-7-yl)methanesulfona te (3v)



General procedure 18 was followed to obtain **3v** (66.5 mg, 0.21 mmol, 69 %) as a white solid. **Mp** 210–211 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.22 (s, 1H, Ar-H), 6.72 (s, 1H, Ar-H), 5.93 (d, J = 13.9 Hz, 2H, O-CH₂), 3.04 (s, 3H, N-CH₃), 3.00 (d, J = 13.8 Hz, 1H, CH₂), 2.79 (d, J = 13.8 Hz, 1H, CH₂), 1.26 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 180.0, 146.6, 142.1, 137.7, 125.7, 107.7, 100.9, 92.3, 57.4, 46.7, 26.8, 24.3. **HRMS** (ESI) calcd for C₁₂H₁₂NO₆S [M-Na]⁻ 298.0391, found 298.0396.

Sodium

(6,8-dimethyl-7-oxo-7,8-dihydro-6H-[1,3]dioxolo[4,5-g]indol-6-yl)methanesulfon ate (3v')



General procedure 18 was followed to obtain **3v**' (26.0 mg, 0.08 mmol, 27 %) as a white solid. **Mp** 210–211 °C.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 6.70 (d, J = 8.0 Hz, 1H, Ar-H), 6.29 (d, J = 8.0 Hz, 1H, Ar-H), 5.96 (s, 1H, O-CH₂), 5.86 (s, 1H, O-CH₂), 3.10 (d, J = 13.8 Hz, 1H, CH₂), 3.01 (s, 3H, N-CH₃), 2.73 (d, J = 13.8 Hz, 1H), 1.19 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 178.3, 143.8, 143.6, 139.2, 114.2, 106.1, 101.4, 99.6, 57.2, 45.2, 26.9, 24.3. **HRMS** (ESI) calcd for C₁₂H₁₂NO₆S [M-Na]⁻ 298.0391, found 298.0396.

Sodium

(1-(4,6-dimethylpyrimidin-2-yl)-3-methyl-2-oxoindolin-3-yl)methanesulfonate (3w)



General procedure 18 was followed to obtain **3w** (52.0 mg, 0.14 mmol, 47 %) as a colorless oil.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.64 (dd, J = 7.5, 0.9 Hz, 1H, Ar-H), 7.33 (d, J = 7.7 Hz, 1H, Ar-H), 7.29 (s, 1H, Ar-H), 7.21 – 7.16 (m, 1H, Ar-H), 7.07 – 7.04 (m, 1H, Ar-H), 3.20 (d, J = 13.9 Hz, 1H, CH₂), 3.03 (d, J = 13.9 Hz, 1H, CH₂), 2.50 (s, 6H, Ar-CH₃), 1.41 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 178.3, 168.6, 154.7, 140.2, 132.6, 126.9, 125.3, 122.5, 118.3, 118.3, 111.2, 56.9, 46.5, 24.9, 23.4, 23.3. **HRMS** (ESI) calcd for C₁₆H₁₆N₃O₄S [M-Na]⁻ 346.0867, found 346.0864.

Sodium

((*R*/*S*)-1-((*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-3-methyl-2-oxoindolin-3-yl) methanesulfonate

(3x)



General procedure 18 was followed to obtain 3x (106.2 mg, 0.25 mmol, 88 %) as a

colorless oil.

¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.75 (dd, J = 7.5, 0.9 Hz, 1H, Ar-H), 7.17 – 7.07 (m, 6H, Ar-H), 6.92 – 6.88 (m, 1H, Ar-H), 6.82 (d, J = 3.2 Hz, 1H, Ar-H), 5.31 (t, J = 11.2 Hz, 1H, N-CH), 3.65 (s, 3H, O-CH₃), 3.35 – 3.31 (m, 2H), 2.84 (d, J = 14.0 Hz, 1H), 2.37 (d, J = 14.0 Hz, 1H), 1.32 (s, 3H). ¹**H NMR** (400 MHz, DMSO-*d6*) δ 7.72 (dd, J = 7.4, 0.8 Hz, 1H, Ar-H), 7.17 – 7.07 (m, 6H, Ar-H), 6.92 – 6.88 (m, 1H, Ar-H), 6.84 (d, J = 3.2 Hz, 1H, Ar-H), 5.31 (t, J = 11.2 Hz, 1H, N-CH), 3.66 (s, 3H, O-CH₃), 3.46 – 3.42 (m, 2H), 2.96 (d, J = 14.0 Hz, 1H), 2.49 (d, J = 14.0 Hz, 1H), 1.14 (s, 3H). ¹³**C NMR** (100 MHz, DMSO-*d6*) δ 179.8, 170.2, 141.5, 137.4, 133.4, 129.5, 129.5, 128.5, 127.5, 126.9, 126.7, 121.9, 108.8, 56.5, 54.6, 52.9, 46.2, 33.8, 22.5. **HRMS** (ESI) calcd for C₂₀H₂₀NO₆S [M-Na]⁻ 402.1017, found 402.1019.

5.2 General Procedure 19 for Sulfonamidation of Substrates 1



Under argon atmosphere, to a 10 mL Schlenk tube was added 1 (0.3 mmol, 1.0 equiv), aliphatic sulfamoyl chloride (0.75 mmol, 2.5 equiv), NaOAc (61.5 mg, 0.75 mmol, 2.5 equiv), Ir(btp)₂Ala (4.5 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixtue was stirred at room temperature under 25 W blue LED irradiation for 24 hours, followed by the addition of H₂O (20 mL), and extracted with DCM (10 mL \times 3). The combined organic layer was washed with brine (10 mL \times 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (4:1~2:1, v/v) as the eluent to give 4.

1-(1,3-Dimethyl-2-oxoindolin-3-yl)-N,N-dimethylmethanesulfonamide (4a)



General procedure 19 was followed to obtain 4a (79.7 mg, 0.28 mmol, 94 %) as a

white solid. **Mp** 104–106 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.29 – 7.24 (m, 2H, Ar-H), 7.08 – 7.04 (m, 1H, Ar-H), 6.85 (d, *J* = 7.7 Hz, 1H, Ar-H), 3.23 (s, 3H, CON-CH₃), 2.92 (d, *J* = 13.3 Hz, 1H, CH₂), 2.73 (d, *J* = 13.3 Hz, 1H, CH₂), 2.04 (s, 6H, N-CH₃), 1.28 (s, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 178.3, 143.1, 130.6, 128.7, 124.1, 122.6, 108.5, 54.0, 45.6, 37.0, 26.6, 25.0. **HRMS** (ESI) calcd for C₁₃H₁₉N₂O₃S [M+H]⁺ 283.1111, found 283.1116.

1-(5-Fluoro-1,3-dimethyl-2-oxoindolin-3-yl)-*N*,*N*-dimethylmethanesulfonamide (4b)



General procedure 19 was followed to obtain 4b (76,7 mg, 0.26 mmol, 85%) as a white solid. Mp 124–125 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.18 (dd, J = 8.0, 2.6 Hz, 1H, Ar-H), 7.06 – 6.99 (m, 1H, Ar-H), 6.80 (dd, J = 8.5, 4.1 Hz, 1H, Ar-H), 3.53 (d, J = 14.1 Hz, 1H, CH₂), 3.38 (d, J = 14.1 Hz, 1H, CH₂), 3.24 (s, 3H, CON-CH₃), 2.71 (s, 6H, N-CH₃), 1.45 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.9, 159.2 (d, J = 240.7 Hz, 1C), 139.0, 132.2 (d, J = 7.3 Hz, 1C), 116.0 (d, J = 24.1 Hz, 1C), 112.5 (d, J = 15.4 Hz, 1C), 108.91 (d, J = 9.3 Hz, 1C), 53.5, 46.0, 37.1, 26.7, 24.8. **HRMS** (ESI) calcd for C₁₃H₁₈FN₂O₃S [M+H]⁺ 301.1017, found 301.1011.

1-(5-Chloro-1,3-dimethyl-2-oxoindolin-3-yl)-*N*,*N*-dimethylmethanesulfonamide (4c)



General procedure 19 was followed to obtain 4c (84.6 mg, 0.27 mmol, 89 %) as a white solid. Mp 183–184 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, J = 2.1 Hz, 1H, Ar-H), 7.29 (dd, J = 8.3, 2.1 Hz, 1H, Ar-H), 6.81 (d, J = 8.3 Hz, 1H, Ar-H), 3.54 (d, J = 14.2 Hz, 1H, CH₂), 3.39 (d, J = 14.2 Hz, 1H, CH₂), 3.24 (s, 3H, CON-CH₃), 2.70 (s, 6H, N-CH₃), 1.44 (s, 3H,

CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 177.6, 141.6, 132.0, 128.4, 127.8, 124.5, 109.2, 53.6, 45.6, 36.8, 26.5, 24.7. HRMS (ESI) calcd for C₁₃H₁₈ClN₂O₃S [M+H]⁺ 317.0721, found 317.0727.

1-(5-Bromo-1,3-dimethyl-2-oxoindolin-3-yl)-*N*,*N*-dimethylmethanesulfonamide (4d)



General procedure 19 was followed to obtain **4d** (94.4 mg, 0.26 mmol, 87 %) as a white solid. **Mp** 207–210 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.50 (d, J = 1.9 Hz, 1H, Ar-H), 7.44 (dd, J = 8.3, 2.0 Hz, 1H, Ar-H), 6.76 (d, J = 8.3 Hz, 1H, Ar-H), 3.54 (d, J = 14.2 Hz, 1H, CH₂), 3.38 (d, J = 14.2 Hz, 1H, CH₂), 3.23 (s, 3H, CON-CH₃), 2.69 (s, 6H, N-CH₃), 1.43 (s, 3H, CH₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 177.7, 142.3, 132.6, 131.5, 127.4, 115.3, 109.9, 53.8, 45.7, 37.0, 26.7, 24.9. **HRMS** (ESI) calcd for C₁₃H₁₈BrN₂O₃S [M+H]⁺ 361.0216, found 361.0219.

N,*N*-Dimethyl-1-(1,3,5-trimethyl-2-oxoindolin-3-yl)methanesulfonamide (4e)



General procedure 19 was followed to obtain 4e (79.2 mg, 0.27 mmol, 89 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.21 (s, 1H, Ar-H), 7.11 (d, J = 7.9 Hz, 1H, Ar-H), 6.77 (d, J = 7.9 Hz, 1H, Ar-H), 3.54 (d, J = 14.2 Hz, 1H, CH₂), 3.40 (d, J = 14.2 Hz, 1H, CH₂), 3.23 (s, 3H, CON-CH₃), 2.66 (s, 6H, N-CH₃), 2.37 (s, 3H, CH₃), 1.43 (s, 3H, Ar-CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.2, 140.7, 132.1, 130.6, 129.0, 124.9, 108.2, 54.0, 45.6, 37.0, 26.6, 25.0, 21.2. **HRMS** (ESI) calcd for C₁₄H₂₁N₂O₃S [M+H]⁺ 297.1267, found 297.1262.

1-(5-Cyano-1,3-dimethyl-2-oxoindolin-3-yl)-*N*,*N*-dimethylmethanesulfonamide (4f)



General procedure 19 was followed to obtain **4f** (79.4 mg, 0.26 mmol, 86 %) as a white solid. **Mp** 224–226 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.66 (d, J = 1.4 Hz, 1H, Ar-H), 7.64 (s, 1H, Ar-H), 6.95 (d, J = 8.0 Hz, 1H, Ar-H), 3.56 (d, J = 14.1 Hz, 1H, CH₂), 3.40 (d, J = 14.1 Hz, 1H, CH₂), 3.28 (s, 3H, CON-CH₃), 2.74 (s, 6H, N-CH₃), 1.45 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.1, 147.1, 134.0, 131.6, 127.7, 119.1, 108.9, 105.9, 53.5, 45.3, 37.1, 26.8, 24.7. **HRMS** (ESI) calcd for C₁₄H₁₈N₃O₃S [M+H]⁺ 308.1063, found 308.1068.

1-(1,3-Dimethyl-2-oxo-5-(trifluoromethyl)indolin-3-yl)-*N*,*N*-dimethylmethanesulf onamide (4g)



General procedure 19 was followed to obtain **4g** (96.8 mg, 0.28 mmol, 92 %) as a white solid. **Mp** 197–198 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.62 (d, J = 8.0 Hz, 1H, Ar-H), 7.60 (s, 1H, Ar-H), 6.96 (d, J = 8.6 Hz, 1H, Ar-H), 3.59 (d, J = 14.2 Hz, 1H, CH₂), 3.44 (d, J = 14.2 Hz, 1H, CH₂), 3.29 (s, 3H, CON-CH₃), 2.67 (s, 6H, N-CH₃), 1.46 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.3, 146.3, 131.1, 130.9, 128.9, 126.4, 121.3, 108.3, 53.8, 45.5, 36.9, 26.8, 24.9. **HRMS** (ESI) calcd for C₁₄H₁₈F₃N₂O₃S [M+H]⁺ 351.0985, found 351.0987.

Methyl

3-((*N*,*N*-dimethylsulfamoyl)methyl)-1,**3**-dimethyl-2-oxoindoline-5-carboxylate (**4**h)



General procedure 19 was followed to obtain 4h (90.0 mg, 0.26 mmol, 88 %) as a white solid. Mp 205–207 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.08 (dd, J = 8.2, 1.5 Hz, 1H, Ar-H), 8.02 (d, J = 1.4 Hz, 1H, Ar-H), 6.93 (d, J = 8.2 Hz, 1H, Ar-H), 3.91 (s, 3H, -OCH₃), 3.61 (d, J = 14.1 Hz, 1H, CH₂), 3.45 (d, J = 14.2 Hz, 1H, CH₂), 3.29 (s, 3H, CON-CH₃), 2.66 (s, 6H, N-CH₃), 1.45 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.55, 166.76, 147.38, 131.41, 130.50, 125.23, 124.54, 108.10, 53.96, 52.08, 45.34, 36.95, 26.80, 25.02. **HRMS** (ESI) calcd for C₁₅H₂₁N₂O₅S [M+H]⁺ 341.1166, found 341.1163.

1-(1,3-Dimethyl-5-nitro-2-oxoindolin-3-yl)-N,N-dimethylmethanesulfonamid (4i)



General procedure 19 was followed to obtain 4i (77.6 mg, 0.24 mmol, 79 %) as a white solid. Mp 209–210 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.31 (dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 8.26 (d, J = 2.2 Hz, 1H, Ar-H), 6.97 (d, J = 8.6 Hz, 1H, Ar-H), 3.62 (d, J = 14.1 Hz, 1H, CH₂), 3.46 (d, J = 14.1 Hz, 1H, CH₂), 3.32 (s, 3H, CON-CH₃), 2.73 (s, 6H, N-CH₃), 1.48 (s, 3H, CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.5, 148.9, 131.4, 125.9, 124.7, 120.1, 108.1, 53.6, 45.5, 37.1, 27.0, 24.8. **HRMS** (ESI) calcd for C₁₃H₁₈N₃O₅S [M+H]⁺ 328.0962, found 328.0969.

1-(5-Methoxy-1,3-dimethyl-2-oxoindolin-3-yl)-N,N-dimethylmethanesulfonamide (4j)



General procedure 19 was followed to obtain 4j (49.7 mg, 0.16 mmol, 53 %) as a

white solid. Mp 126–127 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.05 (d, J = 2.4 Hz, 1H, Ar-H), 6.84 (dd, J = 8.5, 2.4 Hz, 1H, Ar-H), 6.78 (d, J = 8.5 Hz, 1H, Ar-H), 3.81 (s, 3H, -OCH₃), 3.52 (d, J = 14.1 Hz, 1H, CH₂), 3.40 (d, J = 14.2 Hz, 1H, CH₂), 3.23 (s, 3H, CON-CH₃), 2.69 (s, 6H, N-CH₃), 1.44 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.9, 156.0, 136.6, 132.0, 113.0, 111.8, 108.7, 55.9, 53.9, 46.0, 37.0, 26.6, 24.9. **HRMS** (ESI) calcd for C₁₄H₂₁N₂O₄S [M+H]⁺ 313.1217, found 313.1224.

1-(7-Fluoro-1,3-dimethyl-2-oxoindolin-3-yl)-*N,N*-dimethylmethanesulfonamide (4k)



General procedure 19 was followed to obtain 4k (36.9 mg, 0.12 mmol, 41 %) as a white solid. Mp 92–94 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.18 – 7.16 (m, 1H, Ar-H), 7.09 – 6.99 (m, 2H, Ar-H), 3.57 (d, J = 14.1 Hz, 1H, 3.46 (d, J = 2.7 Hz, 3H, CON-CH₃), CH₂), 3.39 (d, J = 14.1 Hz, 1H, CH₂), 2.71 (s, 6H, N-CH₃), 1.44 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 176.9, 146.9 (d, J = 242.1 Hz, 1C), 132.3 (d, J = 4.1 Hz, 1C), 128.8 (d, J = 4.2 Hz, 1C), 122.1 (d, J = 7.7 Hz, 1C), 118.9 (d, J = 3.5 Hz, 1C), 115.7, 115.5, 76.3, 76.0, 75.7, 52.9, 44.8, 36.0, 28.1, 24.2. **HRMS** (ESI) calcd for C₁₃H₁₈FN₂O₃S [M+H]⁺ 301.1017, found 301.1015.

1-(5,7-Difluoro-1,3-dimethyl-2-oxoindolin-3-yl)-*N*,*N*-dimethylmethanesulfonamid e (4l)



General procedure 19 was followed to obtain **41** (45.9 mg, 0.14 mmol, 48 %) as a white solid. **Mp** 173–174 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 6.53 (dd, J = 9.6, 4.8 Hz, 1H, Ar-H), 6.47 (dd, J = 8.4 Hz 4.4 Hz, 1H, Ar-H), 3.58 (q, J = 14.0 Hz, 2H, CH₂), 3.23 (s, 3H, CON-CH₃), 2.70 (s, 6H, N-CH₃), 1.47 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.8, 145.88 – 145.75 (m, 1C), 111.5, 111.3 (d, J = 20.4 Hz, 1C), 97.6, 97.6 (d, J = 30.4 Hz, 1C), 93.7 (d, J = 26.6 Hz, 1C), 52.9, 44.3, 36.8, 26.9, 23.4. **HRMS** (ESI) calcd for C₁₃H₁₇F₂N₂O₃S [M+H]⁺ 319.0922, found 319.0927.

1-(1,3-Dimethyl-2-oxo-7-phenylindolin-3-yl)-*N*,*N*-dimethylmethanesulfonamide (4m)



General procedure 19 was followed to obtain 4m (58.1 mg, 0.16 mmol, 54 %) as a white solid. Mp 140–141 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.41 – 7.35 (m, 6H, Ar-H), 7.15 – 7.12 (m, 2H, Ar-H), 3.53 (q, *J* = 14.1 Hz, 2H, CH₂), 2.77 (s, 3H, CON-CH₃), 2.69 (s, 6H, N-CH₃), 1.48 (s, 3H, CH₃). ¹³**C** NMR (100 MHz, CDCl₃) δ 179.3, 140.2, 138.9, 131.7, 131.5, 127.8, 127.9, 125.9, 123.1, 121.9, 54.4, 45.0, 37.0, 30.6, 25.4. **HRMS** (ESI) calcd for C₁₉H₂₃N₂O₃S [M+H]⁺ 359.1424, found 359.1429.

1-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H-benzo[g]indol-3-yl)-*N*,*N*-dimethylmethane sulfonamide (4n)



General procedure 19 was followed to obtain 4n (60.9 mg, 0.18 mmol, 51 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.76 (d, J = 8.1 Hz, 1H, Ar-H), 7.58 – 7.54 (m, 1H, Ar-H), 7.52 (d, J = 8.2 Hz, 1H, Ar-H), 7.48 (d, J = 7.3 Hz, 1H, Ar-H), 7.45 – 7.41 (m, 1H, Ar-H), 6.98 (d, J = 7.6 Hz, 1H, Ar-H), 4.35 (d, J = 14.1 Hz, 1H, CH₂), 3.64 (d, J = 14.1 Hz, 1H, CH₂), 3.57 (s, 3H, CON-CH₃), 2.57 (s, 6H, N-CH₃), 1.67 (s, 3H, CH₃).

¹³C NMR (100 MHz, CDCl₃) δ 171.3, 136.4, 134.5, 133.5, 126.9, 126.6, 126.5, 123.5, 122.8, 119.2, 108.9, 58.1, 45.6, 36.9, 33.6, 30.0. HRMS (ESI) calcd for C₁₇H₂₁N₂O₃S [M+H]⁺ 333.1267, found 333.1265.

1-(1,3-Dimethyl-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-*N*,*N*-dimethyl methanesulfonamide (40)



General procedure 19 was followed to obtain **40** (52.7 mg, 0.19 mmol, 62 %) as a white solid. **Mp** 134–135 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.23 (d, J = 4.4 Hz, 1H, Ar-H), 7.70 (d, J = 6.4 Hz, 1H, Ar-H), 7.03 – 7.00 (m, 1H, Ar-H), 3.50 (d, J = 14.1 Hz, 1H, CH₂), 3.41 (d, J = 14.0 Hz, 1H, CH₂), 3.34 (s, 3H, CON-CH₃), 2.73 (s, 6H, N-CH₃), 1.49 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.8, 156.1, 147.3, 132.1, 124.9, 118.1, 52.9, 45.1, 36.9, 25.5, 23.9. **HRMS** (ESI) calcd for C₁₂H₁₈N₃O₃S [M+H]⁺ 284.1063, found 284.1068.

1-(1,3-Dimethyl-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]quinolin-3-yl)-*N*,*N*-dimethyl methanesulfonamide (4p)



General procedure 19 was followed to obtain 4p (67.1 mg, 0.20 mmol, 67 %) as a white solid. Mp 120–121 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.09 (s, 1H, Ar-H), 7.95 (d, J = 8.4 Hz, 1H, Ar-H), 7.79 (d, J = 7.9 Hz, 1H, Ar-H), 7.69 – 7.62 (m, 1H, Ar-H), 7.45–7.41 (m, 1H, Ar-H), 3.53 (q, J = 14.2 Hz, 2H, CH₂), 3.45 (s, 3H, CON-CH₃), 2.73 (s, 6H, N-CH₃), 1.57 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.2, 155.7, 147.1, 132.0, 129.9, 128.4, 127.7, 126.1, 125.6, 124.8, 53.2, 44.8, 37.2, 26.0, 24.6. **HRMS** (ESI) calcd for C₁₆H₂₀N₃O₃S [M+H]⁺ 334.1220, found 334.1223.

N,N-Dimethyl-1-(3-methyl-2-oxo-1-phenylindolin-3-yl)methanesulfonamide (4q)



General procedure 19 was followed to obtain 4q (81.6 mg, 0.24 mmol, 79 %) as a white solid. Mp 151–153 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.55 – 7.46 (m, 4H, Ar-H), 7.42 (d, J = 7.2 Hz, 2H, Ar-H), 7.23 (d, J = 7.7, 1H, Ar-H), 7.16– 7.12 (m, 1H, Ar-H), 6.83 (d, J = 7.8 Hz, 1H, Ar-H), 3.69 (d, J = 14.1 Hz, 1H, CH₂), 3.50 (d, J = 14.1 Hz, 1H, CH₂), 2.69 (s, 6H, N-CH₃), 1.55 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.8, 143.5, 134.6, 130.2, 129.6, 128.6, 128.2, 126.8, 124.1, 122.9, 109.9, 54.3, 45.7, 37.0, 25.5. **HRMS** (ESI) calcd for C₁₈H₂₁N₂O₃S [M+H]⁺ 345.1267, found 345.1271.

1-(1-Benzyl-3-methyl-2-oxoindolin-3-yl)-N,N-dimethylmethanesulfonamide (4r)



General procedure 19 was followed to obtain 4r (80.7 mg, 0.23 mmol, 75 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.40 (d, J = 7.1 Hz, 1H, Ar-H), 7.36 – 7.29 (m, 4H, Ar-H), 7.29 – 7.25 (m, 1H, Ar-H), 7.18 – 7.16(m, 1H, Ar-H), 7.09 – 7.05 (m, 1H, Ar-H), 6.74 (d, J = 7.8 Hz, 1H, Ar-H), 5.04 (d, J = 15.7 Hz, 1H, N-CH₂), 4.87 (d, J = 15.7 Hz, 1H, N-CH), 3.61 (d, J = 14.2 Hz, 1H, CH₂), 3.47 (d, J = 14.2 Hz, 1H, CH₂), 2.66 (s, 6H, N-CH₃), 1.50 (s, 3H, CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.4, 142.3, 135.8, 130.6, 128.8, 128.6, 127.6, 127.4, 124.1, 122.6, 109.7, 53.7, 45.7, 44.2, 37.0, 25.6. **HRMS** (ESI) calcd for C₁₉H₂₃N₂O₃S [M+H]⁺ 359.1424, found 359.1429. **Ethyl 3-((***N***,***N***-dimethylsulfamoyl)methyl)-3-methyl-2-oxoindoline-1-carboxylate (4s)**



General procedure 19 was followed to obtain 4s (84.0 mg, 0.24 mmol, 79 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.45 (d, J = 7.0 Hz, 1H, Ar-H), 7.31 – 7.29 (m, 1H, Ar-H), 7.15 – 7.11 (m, 1H, Ar-H), 6.77 (d, J = 7.8 Hz, 1H, Ar-H), 4.68 (d, J = 17.6 Hz, 1H, SO₂-CH₂), 4.30 (d, J = 17.6 Hz, 1H, SO₂-CH₂), 4.22 (q, J = 7.1 Hz, 2H, O-CH₂), 3.50 (dd, J = 36.8, 14.2 Hz, 2H, N-CH₂), 2.67 (s, 6H, N-CH₃), 1.50 (s, 3H, CH₃), 1.26 (d, J = 7.1 Hz, 3H, OCH₂-CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.3, 167.6, 141.8, 130.4, 128.7, 124.5, 123.0, 108.5, 61.8, 53.7, 45.7, 41.6, 37.0, 25.1, 14.1. **HRMS** (ESI) calcd for C₁₆H₂₃N₂O₅S [M+H]⁺ 355.1322, found 355.1328.

N,*N*-Dimethyl-1-(1-methyl-2-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)methanesulfonamide (4t)



General procedure 19 was followed to obtain 4t (84.2 mg, 0.27 mmol, 91 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.27 – 7.23 (d, *J* = 7.4 Hz, 1H, Ar-H), 7.06 (d, *J* = 7.4 Hz, 1H, Ar-H), 7.02 – 6.98 (m, 1H, Ar-H), 3.75 (t, *J* = 5.2 Hz, 2H, N-CH₂), 3.50 (d, *J* = 14.1 Hz, 1H, SO₂-CH₂), 3.40 (d, *J* = 14.1 Hz, 1H, SO₂-CH₂), 2.80 (t, *J* = 5.2 Hz, 2H, Ar-CH₂), 2.69 (s, 6H, N-CH₃), 2.06 – 1.99 (m, 2H, ArCH₂-CH₂), 1.46 (s, 3H, CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 177.1, 138.9, 129.2, 127.5, 122.09, 122.06, 120.5, 53.7, 46.7, 39.2, 37.0, 24.6, 24.5, 21.1. **HRMS** (ESI) calcd for C₁₅H₂₁N₂O₃S [M+H]⁺ 309.1267, found 309.1265.

N,*N*-Dimethyl-1-(7-methyl-6-oxo-6,7,11,12-tetrahydrobenzo[6,7]azepino[3,2,1-hi] indol-7-yl)methanesulfonamide (4u)



General procedure 19 was followed to obtain **4u** (97.8 mg, 0.26 mmol, 88 %) as a white solid. **Mp** 166–167 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.91 (br, 1H, Ar-H), 7.32 – 7.27 (m, 1H, Ar-H), 7.24 – 7.15 (m, 3H, Ar-H), 7.10 – 7.02 (m, 2H, Ar-H), 3.74 (d, J = 14.1 Hz, 1H, SO₂-CH₂), 3.50 (d, J = 14.1 Hz, 1H, SO₂-CH₂), 3.07 – 3.03 (m, 4H, Ar-CH₂), 2.68 (s, 6H, N-CH₃), 1.51 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.5, 140.4, 130.6, 129.3, 126.6, 126.55, 125.3, 122.3, 121.5, 54.7, 45.4, 36.9, 33.8, 33.8, 26.3. **HRMS** (ESI) calcd for C₂₀H₂₃N₂O₃S [M+H]⁺ 371.1424, found 371.1427.

N,*N*-Dimethyl-1-(1-methyl-2-oxo-3-phenylindolin-3-yl)methanesulfonamide (4v)



General procedure 19 was followed to obtain 4v (33.0 mg, 0.1 mmol, 32 %) as a white solid. Mp 151–152 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.46 (d, J = 7.8 Hz, 1H, Ar-H), 7.42 – 7.36 (m, 3H, Ar-H), 7.33 – 7.28 (m, 3H, Ar-H), 7.21– 7.17 (m, 1H, Ar-H), 6.94 (d, J = 7.8 Hz, 1H, Ar-H), 4.14 (d, J = 14.1 Hz, 1H, CH₂), 3.77 (d, J = 14.1 Hz, 1H, CH₂), 3.25 (s, 3H, N-CH₃), 2.70 (s, 6H, N-CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 176.5, 144.2, 138.3, 129.2, 128.9, 128.1, 128.0, 126.6, 126.5, 122.4, 108.8, 54.8, 52.8, 37.1, 26.9. **HRMS** (ESI) calcd for C₁₈H₂₁N₂O₃S [M+H]⁺ 345.1267, found 345.1273.

1,3-Dimethyl-3-((pyrrolidin-1-ylsulfonyl)methyl)indolin-2-one (4w)



General procedure 19 was followed to obtain 4w (73.1 mg, 0.24 mmol, 79 %) as colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.38 (d, J = 7.4 Hz, 1H, Ar-H), 7.33 – 7.31 (m, 1H, Ar-H), 7.12 – 7.09 (m, 1H, Ar-H), 6.89 (d, J = 7.8 Hz, 1H, Ar-H), 3.60 (d, J = 14.3 Hz, 1H, CH₂), 3.50 (d, J = 14.3 Hz, 1H, CH₂), 3.25 (s, 3H, N-CH₃), 3.16 – 3.10 (m, 2H, N-CH₂), 3.09 – 3.01 (m, 2H, N-CH₂), 1.83 – 1.77 (m, 4H, NCH₂-CH₂), 1.43 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.1, 143.0, 130.4, 128.4, 123.9, 122.3, 108.3, 55.0, 47.1, 45.5, 26.4, 25.6, 24.9. **HRMS** (ESI) calcd for C₁₅H₂₁N₂O₃S [M+H]⁺ 309.1267, found 309.1265.

1,3-Dimethyl-3-((piperidin-1-ylsulfonyl)methyl)indolin-2-one (4x)



General procedure 19 was followed to obtain 4x (80.3 mg, 0.25 mmol, 83 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.42 (d, J = 7.4 Hz, 1H, Ar-H), 7.33– 7.29 (m, 1H, Ar-H), 7.13– 7.09 (m, 1H, Ar-H), 6.88 (d, J = 7.8 Hz, 1H, Ar-H), 3.51 (d, J = 14.1 Hz, 1H, CH₂), 3.38 (d, J = 14.1 Hz, 1H, CH₂), 3.25 (s, 3H, N-CH₃), 3.08 – 2.98 (m, 4H, N-CH₂), 1.54 (dd, J = 10.3, 5.5 Hz, 6H, NCH₂-CH₂CH₃), 1.44 (s, 3H, CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.3, 143.1, 130.6, 128.6, 124.3, 122.6, 108.4, 54.9, 46.3, 45.7, 26.6, 25.5, 24.9, 23.7. **HRMS** (ESI) calcd for C₁₆H₂₃N₂O₃S [M+H]⁺ 323.1424, found 323.1429.

1,3-Dimethyl-3-((morpholinosulfonyl)methyl)indolin-2-one (4y)



General procedure 19 was followed to obtain 4y (86.6 mg, 0.27 mmol, 89 %) as a white solid. Mp 145–136 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.40 (d, J = 7.4 Hz, 1H, Ar-H), 7.37 – 7.29 (m, 1H, Ar-H), 7.14 – 7.11 (m, 1H, Ar-H), 6.89 (d, J = 7.8 Hz, 1H, Ar-H), 3.64 (t, J = 4.7 Hz, 4H, O-CH₂), 3.58 (d, J = 14.1 Hz, 1H, CH₂), 3.42 (d, J = 14.1 Hz, 1H, CH₂), 3.13 –

3.00 (m, 4H, N-CH₂), 1.44 (s, 3H, CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.0, 142.9, 130.1, 128.5, 124.0, 122.4, 108.3, 66.2, 54.5, 46.4, 45.2, 26.4, 24.8. **HRMS** (ESI) calcd for C₁₅H₂₁N₂O₄S [M+H]⁺ 325.1217, found 325.1213.

5.3 General Procedure 20 for Sulfonylation of Substrates 5a-5g



Under argon atmosphere, to a 10 mL Schlenk tube was added 1 (0.3 mmol, 1.0 equiv), sulfonyl chloride (0.36 mmol, 1.2 equiv), Na₂CO₃ (38.2 mg, 0.36 mmol, 1.2 equiv), Ir{dF(CF₃)ppy}₂(dtbbpy)PF₆(6.7 mg, 0.06 mmol, 2.0 mol%) and 2 mL MeCN, The reaction mixtue was stirred at room temperature under 25 W blue LED irradiation for 36 hours, followed by the addition of H₂O (20 mL), and extracted with DCM (10 mL × 3). The combined organic layer was washed with brine (10 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (8:1~4:1, v/v) as the eluent to give **5**.

1,3-Dimethyl-3-(tosylmethyl)indolin-2-one (5a)



General procedure 20 was followed to obtain 5a (89.9 mg, 0.27 mmol, 91 %) as a white solid. Mp 112–113 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.38 (d, J = 8.3 Hz, 2H, Ar-H), 7.31 – 7.27 (m, 1H, Ar-H), 7.17 (d, J = 8.1 Hz, 2H, Ar-H), 7.09 (d, J = 7.1 Hz, 1H, Ar-H), 6.94 – 6.90 (m, J = 7.5 Hz, 1H, Ar-H), 6.84 (d, J = 7.8 Hz, 1H, Ar-H), 3.85 (d, J = 14.5 Hz, 1H, CH₂), 3.66 (d, J = 14.5 Hz, 1H, CH₂), 3.16 (s, 3H, N-CH₃), 2.39 (s, 3H, Ar-CH₃), 1.39 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.7, 144.4, 143.3, 137.0, 129.6, 129.5, 128.6, 127.8, 124.1, 122.5, 108.4, 61.9, 45.7, 26.6, 25.5, 21.6. **HRMS** (ESI) calcd for C₁₈H₂₀NO₃S [M+H]⁺ 330.1158, found 330.1163.

3-(((4-Methoxyphenyl)sulfonyl)methyl)-1,3-dimethylindolin-2-one (5b)



General procedure 20 was followed to obtain 5b (90.2 mg, 0.26 mmol, 87 %) as a white solid. Mp 103–104 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.40 (d, J = 8.8 Hz, 2H, Ar-H), 7.31 – 7.27 (m, 1H, Ar-H), 7.10 (d, J = 7.4 Hz, 1H, Ar-H), 6.97 – 6.93 (m, 1H, Ar-H), 6.85 – 6.82 (m, 1H, Ar-H), 6.84 – 6.81 (d, J = 8.5 Hz, 2H, Ar-H), 3.86 (d, J = 14.5 Hz, 1H, CH₂), 3.84 (s, 3H, OCH₃), 3.65 (d, J = 14.5 Hz, 1H, CH₂), 3.15 (s, 3H, N-CH₃), 1.38 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 163.5, 143.3, 131.6, 130.1, 129.7, 128.6, 124.2, 122.5, 114.1, 108.4, 62.1, 55.7, 45.7, 26.5, 25.6. **HRMS** (ESI) calcd for C₁₈H₂₀NO₄S [M+H]⁺ 346.1108, found 346.1106.

1,3-Dimethyl-3-(((4-nitrophenyl)sulfonyl)methyl)indolin-2-one (5c)



General procedure 20 was followed to obtain 5c (76.8 mg, 0.21 mmol, 71 %) as a white solid. Mp 221–224 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.19 (d, J = 8.8 Hz, 2H, Ar-H), 7.64 (d, J = 8.8 Hz, 2H, Ar-H), 7.33 – 7.29 (m, 1H, Ar-H), 6.90 – 6.88 (m, 2H, Ar-H), 6.83 – 6.80 (m, 1H, Ar-H), 3.97 (d, J = 14.8 Hz, 1H, CH₂), 3.76 (d, J = 14.8 Hz, 1H, CH₂), 3.22 (s, 3H, N-CH₃), 1.40 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.3, 150.5, 145.5, 143.5, 129.2, 129.0, 124.0, 123.7, 122.5, 108.7, 62.1, 45.5, 26.6, 25.4. **HRMS** (ESI) calcd for C₁₇H₁₇N₂O₅S [M+H]⁺ 361.0853, found 361.0857.

2-(((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)sulfonyl)benzonitrile (5d)



General procedure 20 was followed to obtain **5d** (94.0 mg, 0.28 mmol, 92 %) as a white solid. **Mp** 240–242 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.79 (d, J = 7.6 Hz, 1H, Ar-H), 7.63 – 7.59 (m, 1H, Ar-H), 7.48 – 7.44 (m, J = 7.7 Hz, 1H, Ar-H), 7.34 (d, J = 7.9 Hz, 1H, Ar-H), 7.21 – 7.19 (m, 1H, Ar-H), 6.83 (d, J = 7.9 Hz, 1H, Ar-H), 6.81 (d, J = 7.5 Hz, 1H, Ar-H), 6.68 – 6.64 (m, 1H, Ar-H), 4.09 (q, J = 15.1 Hz, 2H, CH₂), 3.23 (s, 3H, N-CH₃), 1.42 (s, 3H, CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.2, 143.4, 142.2, 134.9, 133.1, 132.9, 129.7, 129.0, 128.8, 123.2, 122.4, 115.7, 110.8, 108.6, 60.6, 45.4, 26.7, 25.2. **HRMS** (ESI) calcd for C₁₈H₁₇N₂O₃S [M+H]⁺ 341.0954, found 341.0959.

3-((Ethylsulfonyl)methyl)-1,3-dimethylindolin-2-one (5e)



General procedure 20 was followed to obtain 5e (72.2 mg, 0.27 mmol, 90 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.28 (m, 2H, Ar-H), 7.15 – 7.08 (m, 1H, Ar-H), 6.91 (d, J = 7.8 Hz, 1H, Ar-H), 3.59 (q, J = 14.5 Hz, 2H, CH₂), 3.26 (s, 3H, N-CH₃), 2.74 – 2.68 (m, 2H, CH₃-CH₂), 1.46 (s, 3H, CH₃), 1.27 (t, J = 7.4 Hz, 3H, SO₂CH₂-CH₃). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.0, 143.4, 130.4, 129.0, 123.5, 122.6, 108.8, 57.8, 49.5, 45.5, 26.6, 25.1, 6.4. **HRMS** (ESI) calcd for C₁₃H₁₈NO₃S [M+H]⁺ 268.1002, found 268.1008.

3-((Isopropylsulfonyl)methyl)-1,3-dimethylindolin-2-one (5f)



General procedure 20 was followed to obtain 5f (58.2 mg, 0.21 mmol, 69 %) as a

colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.41 (d, J = 7.4 Hz, 1H, Ar-H), 7.35 – 7.30 (m, 1H, Ar-H), 7.13 – 7.09 (m, 1H, Ar-H), 6.90 (d, J = 7.8 Hz, 1H, Ar-H), 3.56 (q, J = 14.0 Hz, 2H, CH₂), 3.26 (s, 3H, N-CH₃), 2.91 – 2.84 (m, 1H, CH), 1.46 (s, 3H, CH₃), 1.31 (d, J = 3.8 Hz, 3H, CH-CH₃), 1.29 (d, J = 3.8 Hz, 3H, CH-CH₃). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.2, 143.3, 130.4, 128.9, 123.9, 122.6, 108.6, 77.4, 77.1, 76.7, 55.0, 45.3, 26.6, 25.2, 15.2, 15.0. **HRMS** (ESI) calcd for C₁₄H₂₀NO₃S [M+H]⁺ 282.1158, found 282.1164.

3-((Cyclohexylsulfonyl)methyl)-1,3-dimethylindolin-2-one (5g)



General procedure 20 was followed to obtain 5g (55.9 mg, 0.17 mmol, 58 %) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.40 (d, J = 7.8 Hz, 1H, Ar-H), 7.35 – 7.31 (m, 1H, Ar-H), 7.12 – 7.09 (m, 1H, Ar-H), 6.90 (d, J = 7.8 Hz, 1H, Ar-H), 3.61 (d, J = 14.0 Hz, 1H, CH₂), 3.48 (d, J = 14.0 Hz, 1H, CH₂), 3.26 (s, 3H, N-CH₃), 2.57 – 2.49 (m, J = 8.7, 4.4 Hz, 1H, CH), 2.09 – 2.04 (m, 2H, CH-CH₂), 1.89 – 1.85 (m, 2H, CH-CH₂), 1.71 – 1.63 (m, 2H, CHCH₂-CH₂), 1.46 (s, 3H, CH₃), 1.44 – 1.39 (m, 2H, CHCH₂-CH₂), 1.20 – 1.17 (m, 2H, CHCH₂-CH₂). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.3, 143.3, 130.4, 128.9, 123.8, 122.5, 108.7, 62.9, 55.2, 45.2, 26.6, 25.2, 25.01, 25.00, 24.9, 24.8, 24.76. **HRMS** (ESI) calcd for C₁₇H₂₄NO₃S [M+H]⁺ 322.1471, found 322.1477.

5.4 General Procedure 21 for Sulfonylation of Substrates 5k



Under argon atmosphere, to a 10 mL Schlenk tube was added **1a** (0.3 mmol, 1.0 equiv), trifluoromethanesulfonyl chloride (125.9 mg, 0.75 mmol, 2.5 equiv), NaOAc

(61.5 mg, 0.75 mmol, 2.5 equiv), $Ir(btp)_2Ala$ (4.5 mg, 0.06mmol, 2.0 mol%) and 2 mL MeCN. The reaction mixtue was stirred at room temperature under 25 W blue LED irradiation for 24 hours, followed by the addition of H₂O (20 mL), and extracted with DCM (10 mL). The combined organic layer was washed with brine (10 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography on a silica gel using petroleum ether and ethyl acetate (5:1, v/v) as the eluent to give **5h**.

1,3-Dimethyl-3-(((trifluoromethyl)sulfonyl)methyl)indolin-2-one (5h)



General procedure 21 was followed to obtain 5h (70.1 mg, 0.23 mmol, 76 %) as a vellow oil.

¹**H** NMR (400 MHz, CDCl₃) δ 7.33 – 7.30 (m, 1H, Ar-H), 7.26 (d, J = 3.0 Hz, 1H, Ar-H), 7.11 – 7.07 (m, 1H, Ar-H), 6.88 (d, J = 7.8 Hz, 1H, Ar-H), 3.24 (s, 3H, N-CH₃), 2.86 – 2.76 (m, 1H, CH₂), 2.70 – 2.60 (m, 1H, CH₂), 1.41 (s, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 178.5, 142.8, 131.0, 129.93 – 129.23 (m, 1C), 128.5, 123.6, 122.7, 108.5, 44.4, 40.6 (q, J = 24.1 Hz, 1C), 26.4, 25.0. **HRMS** (ESI) calcd for C₁₂H₁₃FNO [M+H]⁺ 244.0944, found 244.0947.

Reference:

1. (a) Connelly, N. G.; Geiger, W. E. Chemical redox agents for organometallic chemistry. *Chem. Rev.* **1996**, *96*, 877–910. (b) Choi, G. J.; Zhu, Q. L.; Miller, D. C.; Gu, C. J.; Knowles, R. R. Catalytic alkylation of remote C-H bonds enabled by proton-coupled electron transfer. *Nature* **2016**, *539*, 268–271.

2. Brennan, J. L.; Keyes, T. E.; Forster, R. J. Photonic and electrochemical properties of adsorbed [Ru(dpp)₂(Qbpy)]²⁺ luminophores. *Langmuir* **2006**, *22*, 10754–10761.

3. (a) Døssing, A.; Ryu, C. K.; Kudo, S.; Ford, P. C. Competitive bimolecular electron- and energy-transfer quenching of the excited state(s) of the tetranuclear copper(I) cluster Cu₄I₄py₄. Evidence for large reorganization energies in an excited-state electron transfer. *J. Am. Chem. Soc.* **1993**, *115*, 5132–5137. (b) Bruner, B.; Walker, M. B.; Ghimire, M. M.; Zhang, D.; Selke, M.; Klausmeyer, K. K.; Omary,

M. A.; Farmer, P. J. Ligand-based photooxidations of dithiomaltolato complexes of Ru(ii) and Zn(ii): photolytic CH activation and evidence of singlet oxygen generation and quenching. *Dalton Trans.* **2014**, *43*, 11548–11556. (c) Le, C.; Chen, T. Q.; Liang, T.; Zhang, P.; MacMillan, D. W. C. A radical approach to the copper oxidative addition problem: Trifluoromethylation of bromoarenes. Science **2018**, *360*, 1010–1014.

6. MS (ESI) spectrum



x10 ²	+ESI Scan (0.514 min) I	Frag=150.0V dx3.d										
				108.011	1							
3.5-												
3-												
2.5-												
2-												
1.5-												
1-												
0.5												
0.5												
0-	107 995	108	108 005	108.01	108 015	108 02	108 025	108.03	108 035	108 04	108 045	
	107.000	100	100.000	100.01	Co	ounts vs. Mass-to-Cha	rge (m/z)	100.00	100.000	100.01	100.010	







¹³C NMR spectrum of photocatalyst Ir(btp)₂Gly









¹³C NMR spectrum of compound 1b












¹³C NMR spectrum of compound 1f

















¹³C NMR spectrum of compound 1m

















¹³C NMR spectrum of compound 1s



¹³C NMR spectrum of compound 1t







¹³C NMR spectrum of compound 1w









¹³C NMR spectrum of compound 1z











¹³C NMR spectrum of compound 2a



180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 fl (ppm)

¹H NMR spectrum of compound 2a, A¹ and A²

8	97 97 97 98 97 98 97 98
Ϋ́	



¹³C NMR spectrum of compound 2a, A¹ and A²



¹³C NMR spectrum of compound 3a











¹³C NMR spectrum of compound 3f





¹³C NMR spectrum of compound 3h










¹³C NMR spectrum of compound 3m









¹³C NMR spectrum of compound 3q



¹³C NMR spectrum of compound 3r





¹³C NMR spectrum of compound 3t





¹³C NMR spectrum of compound 3v





¹H NMR spectrum of compound 3x





11. ¹H NMR and ¹³C NMR spectrum of Alkylsulfonamide Products ¹H NMR spectrum of compound 4a



¹H NMR spectrum of compound 4c











¹H NMR spectrum of compound 4g



¹H NMR spectrum of compound 4h























¹H NMR spectrum of compound 4r





250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 fl (ppm)








ò -20 -40 -60 -80 fl (ppm)







12. ¹H NMR and ¹³C NMR spectrum of Sulfonyl Products ¹H NMR spectrum of compound 5a

149

60 40 fl (ppm) 20

ò

-20

-40

-60

-80

-120

-100

-140

240

220

200

180

160

140

120

100

80













¹³C NMR spectrum of compound 5g

-178.26	$\int_{-123.84}^{-143.30} 130.43$	77.39 76.76 76.76 76.76 76.76 76.76 76.70 765.16 765.16 25.15 25.00 24.79 24.79 24.76
---------	-----------------------------------	--







¹³C NMR spectrum of compound 5h

5	84 99 10 10 10 10 10 10 10 10 10 10 10 10 10	848	4464040
78	4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	N N 00	4 - 0 0 0 0 0
57		アアア	4444400

